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ABSTRACT: G protein-coupled receptors (GPCRs) are historically the most successful
family of drug targets. In recent times it has become clear that the pharmacology of these
receptors is far more complex than previously imagined. Understanding of the
pharmacological regulation of GPCRs now extends beyond simple competitive agonism
or antagonism by ligands interacting with the orthosteric binding site of the receptor to
incorporate concepts of allosteric agonism, allosteric modulation, signaling bias, constitutive
activity, and inverse agonism. Herein, we consider how evolving concepts of GPCR
pharmacology have shaped understanding of the complex pharmacology of receptors that
recognize and are activated by nonesteriﬁed or “free” fatty acids (FFAs). The FFA family of
receptors is a recently deorphanized set of GPCRs, the members of which are now receiving
substantial interest as novel targets for the treatment of metabolic and inﬂammatory
diseases. Further understanding of the complex pharmacology of these receptors will be
critical to unlocking their ultimate therapeutic potential.
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1. INTRODUCTION
Alongside the multitude of hormones, neurotransmitters, and
other regulatory factors that are generated by cells and tissues
of multicellular organisms to allow integration of communica-
tion, recent years have seen an explosion of information about
the capacity of molecules contained within or derived from
food sources to also regulate and control cellular function and
maintain homeostasis. Key among these are the nonesteriﬁed or
“free” fatty acids, which have long been known to have diverse
eﬀects on many biological processes, including those related to
cardiovascular health, metabolism, and inﬂammation. Although
the fatty acids were traditionally believed to produce their
eﬀects through intracellular targets, it is now clear that they also
activate several cell surface G protein-coupled receptors
(GPCRs). Targeting GPCRs has long been a mainstay of
drug development programs; however, there is growing
appreciation that ligand regulation of these receptors is much
more complex than originally thought, going far beyond simple
competitive ligands binding to the same site as the endogenous
ligand(s). The current review centers on a family of GPCRs
activated by free fatty acids and in particular will examine the
complex pharmacology of both the fatty acid and the synthetic
molecules that regulate the function of these receptors, in
particular as this relates to the ability of these receptors to
regulate metabolism and inﬂammation. The members of this
receptor family have garnered substantial interest as potential
therapeutic targets,1−7 and we will consider how the current
state of knowledge impacts the future potential of developing
ligands targeting these receptors as therapeutics. Finally,
consideration will be given to key areas of both biological
knowledge and pharmacological tools that are still lacking that
would further expand our understanding of this important
family of receptors.
1.1. Fatty Acids
Fatty acids consist of a carboxylic acid linked to an aliphatic tail
of varying chain length. Fatty acids are, therefore, typically
classiﬁed and deﬁned on the basis of their aliphatic chain.
Initially this includes the length of the chain, with short chain
fatty acids (SCFAs) considered those with 6 or less carbon
chains, medium chain fatty acids (MCFAs) having 7−12 carbon
chains, and long chain fatty acids (LCFAs) ≥13 carbon chains.
In addition to chain length, fatty acids also vary in the number
of unsaturations, often broadly classiﬁed into the saturated
(SFA), monounsaturated (MUFA), and polyunsaturated
(PUFA) fatty acids. The position of unsaturation is also
important and typically is deﬁned by how far from the terminal
carbon the ﬁrst unsaturation occurs, where, for example, an
omega (n)−3 fatty acid has its ﬁrst unsaturation three carbon
atoms from the end of the chain. Generally unsaturations in
naturally occurring fatty acids are in the cis conformation;
however, trans fatty acids also occur naturally in the gut of
ruminants, as well as being generated via hydrogenation of
unsaturated fats during food production processes.8,9 Together,
the various combinations of chain length as well as position,
location, and conformation of unsaturations greatly increase the
number of possible unique fatty acids. The ﬁeld of lipidomics
focuses on characterizing the full range of lipid species,
including the fatty acids, in biological samples and how the
amounts and proportions of these may be altered in response
to diet, disease, or other manipulations of the environ-
ment.10−12
The MCFAs and LCFAs are derived either from fat obtained
in the diet or through de novo synthesis, occurring primarily in
the liver.13 While humans are able to synthesize SFAs and
MUFAs, we lack the enzymes required to incorporate
unsaturations at the n−3 and n−6 positions, limiting de novo
synthesis of the various PUFAs required for health.14 Instead,
interconversion of linoleic acid (LA; 18:2n−6) and α-linolenic
acid (aLA; 18:3n−3) obtained through the diet does allow
synthesis of these other PUFAs; hence, LA and aLA are often
described as “essential” (Figure 1). In the body LCFAs are
utilized, through β-oxidation, as a source of energy, serve as key
components of the phospholipids forming cellular membranes,
and are incorporated into triglycerides for energy storage.
Beyond these roles, nonesteriﬁed, i.e., “free” fatty acids, also
have further widespread and pleiotropic roles in the body.
These include acting as the precursors of many signaling
molecules, including resolvins, prostaglandins, and leuko-
trienes,15−17 and acting directly as ligands of various cell
surface and intracellular receptors.18−20 Although quantitatively
relatively minor in amount, PUFAs, such as the n−3 fatty acids,
DHA (22:6n−3) and EPA (20:5n−3) (Figure 1) that are found
in high levels in oily ﬁsh are often linked to positive metabolic
and cardiovascular health outcomes21,22 and hence the
exhortations to include ﬁsh oil in the diet.23 In contrast,
trans-fatty acids are generally considered to be detrimental to
Figure 1. Chemical structures of LCFAs.
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cardiovascular and metabolic health,8,24 and recommendations
are routinely to avoid or limit consumption of such fatty
acids.23 Detailed lipidomic studies have also identiﬁed further
modiﬁed fatty acids with unique biological activity, for example,
fatty acid esters of hydroxy fatty acids (FAHFAs), such as 5-
PAHSA (Figure 1), which despite being present in very low
levels in biological systems has been reported to have anti-
inﬂammatory and antidiabetic activity.25 It is likely that further
speciﬁc but relatively uncommon fatty acids, including the so-
called “platinum-induced fatty acids” (PIFAs), 12-oxo-5,8,10-
heptadecatrienoic acid and hexadeca-4,7,10,13-tetraenoic acid
(16:4n−3) that induce chemotherapeutic resistance26,27 (Figure
1), will be shown to have dramatic eﬀects on cell function and
health. A major challenge going forward will be to deﬁne the
molecular targets for these molecules that account for their
apparently potent and speciﬁc eﬀects and to understand how
they might function in the presence of quantitatively much
higher levels of other fatty acids. A substantial discussion of the
biochemistry of synthesis, interconversion, and generation of
MCFAs and LCFAs and their metabolites is beyond the scope
of this review, but a series of recent reviews provides excellent
primers for those wishing to read further.13,15,16
In contrast to the LCFAs, the SCFAs are produced primarily
via bacterial fermentation of ﬁber in the gut, although
production of acetate through the metabolism of ethanol may
also provide a signiﬁcant source of SCFAs in certain
circumstances (Figure 2). Variation in the composition of gut
microﬂora responsible for SCFA production is now frequently
linked to health and disease,28−30 and many studies are
demonstrating that SCFAs are the key signaling molecules
underlying this link. Therefore, there is considerable interest in
manipulating the microﬂoral balance in the gut as a means to
alter SCFA levels and proﬁle. For example, as certain species of
bacteria are known to favor production of diﬀerent SCFAs,31,32
manipulating bacterial composition to, for example, increase
acetate (C2) production over propionate (C3) and butyrate
(C4), may have substantial eﬀects on health and disease. This is
an area receiving expanding research focus in recent times, not
least because of advances in technologies capable of high-
throughput gene sequencing to deﬁne the diversity of the
microbiota.29
1.2. G Protein-Coupled Receptors
It is frequently noted that GPCRs are the largest family of
transmembrane signaling polypeptides encoded within the
genomes of eukaryotic species.33 Given the now clear-cut
evidence that signal transduction initiated by activation of
GPCRs is not limited to events transduced by subunits of
heterotrimeric G proteins,34,35 the alternative term 7-trans-
membrane domain (7-TMD) receptor is growing in popularity.
This terminology highlights the key architectural feature of this
family of proteins, i.e., that the corresponding gene encodes a
single polypeptide in which an N-terminal domain is located on
the opposite side of the plasma membrane from the C-
terminus. This results in serpentine organization in which the 7-
transmembrane domains are linked by three extracellular and
three intracellular loops (Figure 3). Informatic analysis, based
on the predicted presence of seven hydrophobic domains of
suﬃcient reach to span the plasma membrane and a series of
amino acid signatures highly conserved throughout the
predominant subfamily, allowed prediction that the human
genome would likely contain in the region of 800 distinct genes
encoding GPCRs. Initial drafts and subsequent more detailed
follow-up results have conﬁrmed such predictions.33 The
ubiquity of the 7-TMD design means that GPCRs have
evolved to recognize ligands, chemicals, and stimuli as diverse
as photons, odorants, various ions, aminergic neurotransmitters,
peptide hormones, and small proteins such as chemokines.
Consistent with this, GPCRs control or modulate a vast range
of physiological functions and, based on this, have been
targeted to mask, treat, or ameliorate a broad range of
diseases.36−38
Recent years have seen tremendous breakthroughs in
structural insights into the organization of GPCRs and the
chemical basis of their selective recognition of both natural and
synthetic ligands.39−42 The substantial amounts of the photon-
recognition receptor rhodopsin in rod outer membrane
segments of the eye and its ease of puriﬁcation allowed
crystallization of the inactive state of this GPCR almost a
decade ahead of other GPCRs.43,44 However, development of
Figure 2. Biosynthesis pathways for SCFAs. SCFAs are synthesized
primarily by microbiota present in the gut (left). Nondigestible
polysaccharides are converted into monosaccharides such as glucose,
which undergo glycolysis to produce pyruvate. Fermentation processes
(marked by brown box) convert pyruvate to acetate, propionate, or
butyrate. Under certain circumstances, the SCFA acetate is also
produced in substantial quantities through ethanol metabolism in the
liver (right).
Figure 3. Topology of a GPCR. A GPCR has an extracellular N-
terminus and intracellular C-terminus with 7 membrane spanning
helical domains linked through three extracellular and three intra-
cellular loops (left). Viewed from outside the cell, these TM domains
are arranged in a counterclockwise fashion (right).
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methods including incorporation of well-understood proteins,
such as T4-lysozyme, into the sequence of GPCRs and more
suitable detergents to allow for stability of protein solubilized
from membranes of expression systems has resulted in a large
number of both inactive and active atomic level structures being
deﬁned in recent years.45−47 In general, many of the predictions
derived from work on rhodopsin have been validated across the
broader family of “rhodopsin-like” or “class A” GPCRs. In
essence the 7-TMD helices are organized (as viewed from the
outside of the cell) in a counterclockwise orientation (Figure
3), providing a potential central, predominantly hydrophilic,
cavity at the cell surface that water-soluble ligands may enter to
make speciﬁc chemical interactions that help deﬁne the ligand
binding pocket. The organization of the extracellular loops,
particularly the second extracellular loop (EL2) connecting
transmembrane domains IV and V, is more variable and appears
to play a role in ligand binding and entry to the classical ligand
binding pocket.48,49
Unsurprisingly, given the widespread utilization of this
topological framework, the basic 7-TMD design of the GPCR
superfamily has been modiﬁed in a number of cases to provide
further specialization. For example, in cases such as the group
of protease-activated receptors the ligand for the receptor is
contained and constrained within the N-terminal domain of the
receptor polypeptide, and this is released by cleavage by an
appropriate protease.50 A distinct means to provide signaling
diversity from a single 7-TMD polypeptide is exempliﬁed by
the calcitonin receptor-like receptor which interacts selectively
with either of two peptide hormones, calcitonin gene-related
peptide and adrenomedullin, involved in control of cardiovas-
cular function.51 This selectivity is deﬁned by the interaction of
the 7-TMD element of the receptor with diﬀerent members of
a small group of single TMD receptor activity modulating
polypeptides (RAMPs).52 The basis for the peptide binding
speciﬁcity has recently been explored by X-ray crystallog-
raphy.53 An alternative way to increase diversity still further is
exempliﬁed by cases in which multiple copies of either the same
GPCR sequence or copies of distinct family members can
interact directly to form, respectively, homomers and
heteromers.54 In many cases such interactions alter either the
detailed patterns of recognition of ligands or the regulation of
the receptor polypeptides.55−57
1.3. Complex Pharmacology of GPCRs
As ﬂexible and dynamic proteins with predominantly hydro-
phobic external surfaces, studies on the basis of their
recognition by synthetic chemicals have, in recent years,
uncovered a hitherto unappreciated diversity in the basis and
sites of such interactions. Although classic pharmacological
analysis focused heavily on chemical ligands in which the mode
of interaction could be described mathematically by sub-
stitution for (orthosteric agonism) or prevention of access to
(orthosteric antagonism) the same binding pocket as the
endogenously generated regulators of a GPCR, it is now clear
that the diversity of chemical space can allow a much broader
set of opportunities for interaction. Interactions that occur at a
site or sites distinct from that ﬁlled by the endogenous ligand
are generically described as “allosteric” and such chemicals as
“allosteric ligands”. The location of such allosteric sites can be
varied and, indeed, spatially rather distant from the orthosteric
pocket. For example, pepducins are synthetic peptides
corresponding or closely related to sequences from one of
the intracellular loops of a GPCR58 and interact at the
intracellular side of the receptor.59 By contrast, many other
allosteric chemical ligands bind in close proximity to the
orthosteric binding site but in a nonoverlapping manner.60
Given situations in which binding pockets for orthosteric and
allosteric ligands are in close proximity, considerable eﬀorts
have been expended to identify ligands where binding occurs
across these two locations. Such ligands are frequently termed
“bitopic”61,62 or “dualsteric”.63,64 This has been a particularly
fruitful approach in identifying ligands that are selective
between GPCR subtypes, such as the ﬁve subtypes of
muscarinic receptors, which share acetylcholine as a common
endogenous orthosteric ligand. Allosteric eﬀects of ligands can
also reﬂect interactions between either multiple copies of the
same GPCR65 or interactions of a GPCR with either a second,
molecularly distinct GPCR66 or with other non-GPCR
polypeptides.67
1.3.1. Orthosteric Ligands. As noted above, the binding
pocket for the endogenously produced regulators of GPCRs is
deﬁned as the “orthosteric” site. Although synthetic chemicals
that interact in a noncovalent manner with the receptor and act
to either activate the receptor or block the eﬀects of an
endogenous agonist do not inherently have to bind within the
same region, they frequently do so. The actions of orthosteric
ligands on a GPCR are deﬁned by two key fundamental
properties, their aﬃnity for the receptor and their intrinsic
eﬃcacy, or ability to activate the receptor. In a practical sense,
agonist ligands are those that both have aﬃnity to bind the
receptor and have eﬃcacy to activate the receptor, while
antagonist ligands have aﬃnity but lack intrinsic eﬃcacy. As it is
often not possible to measure these properties directly, the
pharmacology of ligands is instead often characterized through
functional assays, where a concentration−response curve is
generated to establish a potency (EC50), and maximal response
for a ligand. While potency is related to aﬃnity and maximal
response related to intrinsic eﬃcacy, due to the complexities of
functional systems both potency and maximal response vary
depending on the speciﬁc assay system being used. It is
therefore not possible to directly compare the potency of two
ligands at the same receptor unless they have been tested under
exactly the same conditions. Due to this limitation, within the
current review, we will refrain from comparing potency values
of compounds, except in cases where they have been tested as
part of the same study under identical assay conditions.
When studying the pharmacology of orthosteric GPCR
ligands in functional systems there are clear predictions for the
observed response when either an agonist or an antagonist is
coadded. In the case of an orthosteric agonist, this will depend
on the eﬃcacy or maximal response of the synthetic agonist.
When ﬁxed concentrations of a “full” synthetic agonist with
eﬃcacy equal to the endogenous ligand are coapplied with the
endogenous ligand, no shift in the maximal response or potency
will be observed (Figure 4A). In contrast, if a “partial” agonist
with reduced eﬃcacy is used, an increase in the concentration
of endogenous ligand will be needed to displace the competing
partial agonist, resulting in a dextral or “right” shift in the
endogenous agonist concentration response (Figure 4B).
Likewise, if a “super”agonist with enhanced eﬃcacy is used,
again the concentration−response to the endogenous agonist
will be right shifted, but in this case it will manifest as a decrease
in maximal response as the higher eﬃcacy superagonist is
displaced by the lower eﬃcacy endogenous agonist (Figure
4C). A ﬁxed concentration of a competitive orthosteric
antagonist is anticipated to result in a requirement for higher
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concentrations of the endogenous agonist to achieve the same
level of eﬀect, again resulting in a dextral shift in the agonist
concentration−response (Figure 4D). As suﬃciently high
concentrations of agonist should fully displace and overcome
the antagonist eﬀect, this form of competitive antagonism is
often described as being “surmountable”. Although historically
competitive antagonists were viewed as neutral blockers that
simply prevented agonist access to the binding pocket, it is
apparent that many of these compounds are also able to inhibit
ligand-independent activity of a receptor, and such ligands are
now descried as “inverse agonists” (see below in section 1.3.4).
There are well-established mathematical models that can be
used to describe each of these ligand behaviors,68 and indeed,
they remain a mainstay in identifying and describing novel
orthosteric ligands for GPCRs.
1.3.2. Allosteric Ligands.Many synthetic compounds have
aﬃnity to bind a site(s) distinct from the “othosteric” binding
pocket of a GPCR. Such compounds are deﬁned as being
“allosteric”. These may possess intrinsic eﬃcacy, acting as
agonists when added alone (allosteric agonists); they may
apparently have no detectable eﬀects when added alone but
modulate the potency and/or eﬃcacy of the endogenous ligand
when they are both present (allosteric modulator) or, indeed,
they may show both allosteric agonist and modulator behaviors
(Figure 5). Allosteric modulation of orthosteric ligand function
is generally classiﬁed based on two properties, modulation of
orthosteric ligand aﬃnity and modulation of orthosteric ligand
eﬃcacy.69 A modulator may enhance either of these parameters,
acting as a so-called positive allosteric modulator (PAM), or
may decrease them, acting as a negative allosteric modulator
(NAM). Each of the properties of an allosteric ligand, aﬃnity
for the allosteric site, intrinsic eﬃcacy, modulation of
orthosteric ligand eﬃcacy, and modulation of orthosteric ligand
aﬃnity, are independent of each other, and thus, the
pharmacology of these compounds can often be very complex.
As such, a number of operational mathematical models have
been developed to quantitatively describe allosterism for GPCR
ligands. This is a topic that has been reviewed and analyzed in
considerable detail and at length in recent years, and the reader
is directed to excellent reviews that cover the basis and means
of analysis of such eﬀects.70,71
Developing allosteric ligands as either therapeutic or tool
compounds may provide a number of advantages over
orthosteric ligands.4,72−74 Most notably, there are many
examples of receptor families with multiple receptor subtypes,
all binding the same orthosteric ligand. In these cases,
evolutionary pressure to maintain binding of the same
endogenous ligand often necessitates structurally similar
orthosteric binding pockets, and as a result, it can be very
diﬃcult to develop synthetic ligands targeting the orthosteric
binding sites that are markedly selective for one subtype over
another. As allosteric sites are not believed to be under the
same evolutionary pressures, targeting these sites has proven to
be a very useful approach to developing selective compounds
for individual family member subtypes.75
A key advantage of allosteric modulators, particularly related
to their potential as therapeutics, is that by nature their eﬀects
will be saturable and also require the presence of an
endogenous ligand to be manifest. In cases where antagonism
is desired, unlike a competitive orthosteric antagonist, which
will continue to have a greater ability to inhibit a response with
inﬁnitely increasing concentrations, a NAM will only continue
to enhance the level of inhibition until the allosteric site is fully
occupied. In theory, this provides a clear potential to develop
therapeutics with improved safety proﬁles. In cases where
agonism is the desired outcome, developing a modulator that
will enhance the eﬀects of an endogenous ligand will have the
obvious advantage of maintaining the spatial and temporal
Figure 4. Pharmacological characterization of orthosteric ligands.
Simulated concentration response data is shown for an endogenous
agonist coapplied with increasing concentrations (represented by
darker shades) of a full agonist (A), partial agonist (B), superagonist
(C), and antagonist (D). While the full agonist results in no shift in
observed potency for endogenous agonist, each of the others results in
a dextral shift (i.e., to higher concentrations) in its concentration−
response curve.
Figure 5. Pharmacological characterization of allosteric ligands.
Simulated concentration response data are shown for an endogenous
agonist coapplied with increasing concentrations (represented by
darker shades) of a PAM (A), agonist-PAM (B), NAM of aﬃnity (C),
and NAM of eﬃcacy (D). The PAM and agonist-PAM result in left
shifts (i.e., requiring lower concentrations) in the response to the
endogenous agonist, while only the agonist-PAM produces a response
in the absence of an endogenous agonist. The NAM of aﬃnity
produces a dextral shift in potency (i.e., requiring higher
concentrations), while the NAM of eﬃcacy reduces the maximal
response generated by the endogenous agonist. In each case the eﬀect
of the allosteric modulator reaches a maximal level, representative of
full occupancy of the allosteric binding site.
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activation of the endogenous ligand. This may be particularly
relevant for the development of modulators targeting neuro-
transmitter or hormone receptors where the speciﬁc time and
location of activity will be critical.
In addition to the concept that ligands binding to allosteric
sites on the same GPCR may modulate orthosteric ligand
function, it is also now appreciated that ligands binding to the
orthosteric sites of two distinct GPCRs may also modulate each
other in an allosteric manner through receptor heteromers.66
This has been shown to modulate all aspects of receptor
function, including orthosteric ligand aﬃnity, eﬃcacy, and
downstream signaling.54,55 More recent studies have even now
demonstrated that two ligands binding to the same orthosteric
site on a GPCR may allosterically modulate each other through
GPCR homomers.76,77
Adding a further level of complexity, with the increase in
GPCR structural information now available, it is apparent that
in at least some cases the orthosteric and allosteric binding
pockets are in close proximity.60 This has led to the
development of bitopic ligands, engineered to interact
simultaneously with both orthosteric and allosteric binding
sites of the receptor. Such approaches have typically led to the
identiﬁcation of both highly selective compounds and ones
often with unique pharmacology in their ability to favor or bias
receptor activation toward certain signaling pathways over
others.
1.3.3. Bias Ligands. Conformational ﬂexibility of GPCRs
indicates that these proteins exist in either multiple distinct
conformations or, potentially, as a continuum of states.78−80 As
binding of a ligand to a GPCR generally stabilizes the protein,
this implies that diﬀerent ligands could selectively stabilize a
particular conformational state or states and, therefore, enrich a
subset of these at the expense of others. It has become
increasingly clear that the previous view that individual GPCRs
interacted exclusively with one speciﬁc G protein partner is an
oversimpliﬁcation. Indeed, recent studies employing sensors
that report interactions between a GPCR and diﬀerent G
protein α subunits provide evidence, at least in transfected cell
lines, for a very complex pattern of interactions.81 This also
implies that diﬀerent ligands may stabilize receptor conforma-
tions that interact selectively with diﬀerent G proteins and, by
so doing, initiate diﬀerent signaling cascades (Figure 6A).
Beyond this feature of G protein bias, as noted in section 1.2,
GPCRs can also promote signals that occur independently of G
protein activation. Although such signals may derive from
interactions with a variety of cellular proteins, focus has been
predominantly on interactions with arrestins.82 Ligands able to
selectively promote interactions of GPCRs with either an
arrestin or a G protein are therefore biased between these
pathways (Figure 6B) and have been identiﬁed for many
GPCRs.83 Moreover, in at least a number of cases it has been
suggested that in a therapeutic context some of the panoply of
signals that can be generated by ligand activation of a GPCR
may be harmful rather than beneﬁcial.84 Such hypotheses have
resulted in the development and ongoing clinical assessment of
biased ligands at both the angiotensin AT1 receptor and the μ-
opioid receptor.85
1.3.4. Ligand-Independent Constitutive Activity. In
the least complex situation (the so-called “two-state” model)
GPCRs can be viewed as ligand sensors that transit from
inactive to active states upon binding of an agonist chemical. It
follows, therefore, that GPCRs should be able, at least to some
degree, to interconvert between these states spontaneously, and
the degree of agonist-independent signaling observed will
reﬂect the equilibrium between these two states (Figure 7A).
Activity that can be measured in the absence of ligand
interaction with a receptor is thus described as ligand-
independent or constitutive activity. This varies markedly
between diﬀerent GPCRs86,87 and can be modiﬁed markedly by
mutation or within polymorphic variants of the same
receptor.88 Although antagonists were deﬁned initially simply
as ligands that could block agonist activation of a GPCR,
nowadays, in molecular terms an (neutral) antagonist is deﬁned
as a chemical that binds with equal aﬃnity to distinct
conformational states of a receptor and does not favor the
GPCR adopting one state over another. However, it was
recognized that a number of “antagonist” ligands were able to
reduce the level of agonist-independent signal transduction and
therefore were interpreted to selectively stabilize the inactive
ground state of the receptor.89,90 Ligands with this capability
are, therefore, described as inverse agonists (Figure 7B and
7C).
1.4. “Orphan” GPCRs and Receptor Deorphanization
Despite early successes in pairing cloned and expressed GPCRs
with endogenously generated ligands that produced receptor
activation and downstream signaling, the use of “homology
cloning”, in which cDNA generated from tissue extracts was
PCR ampliﬁed using primers based on sequence from the most
highly conserved TMDs of previously cloned 7-TMD proteins,
resulted in the identiﬁcation of a large number of potential
GPCRs for which the activating ligands were unknown. Such
sequences are deﬁned as orphan receptors. A workﬂow of
Figure 6. GPCR biased agonism. GPCR bias agonism may manifest
either as bias signaling through one speciﬁc Gα subunit over another
(A) or as bias signaling toward G protein vs arrestin pathways (B).
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strategies to identify endogenously generated chemicals that
activate such orphan GPCRs is often described as “reverse
pharmacology”.91,92 This might be initiated using sequence
alignment of the orphan polypeptide with other previously
characterized GPCR family members and informatic analysis to
predict potential chemical ligands for the orphan. For example,
sequence alignment of an orphan receptor sequence designated
AXOR35 showed it to be closely related to the previously
characterized histamine H3 receptor. Histamine also potently
activated AXOR35 leading to deorphanization as the histamine
H4 receptor.
93 Similarly, knowledge of the physiological actions
of chemical ligands and of the tissues in which they generate
responses has also been eﬀective in deorphanization programs.
For example, nicotinic acid was known for many years to
interact with and activate Gi-family G proteins in white
adipocytes,94 although the receptor mediating this process was
not. Therefore, testing the responsiveness to nicotinic acid of a
number of previously uncharacterized orphan GPCRs that were
known to be expressed by adipocytes resulted in appreciation
that both HM74 and the closely related HM74A (also known
as GPR109A) could be activated by varying concentrations of
nicotinic acid, with HM74A requiring substantially lower
concentrations to generate responses.91 These receptors have
subsequently been named systematically as hydroxycarboxylic
acid (HCA) receptors,95 based on the accepted true
endogenously produced regulators of these receptors (whereas
nicotinic acid, also known as niacin or vitamin B3, is obtained
from the diet as an essential nutrient). A third receptor,
previously named GPR81, and now designated HCA3, was
shown initially to have very weak potency for nicotinic acid91
but has subsequently been deorphanized as a receptor for lactic
acid.95,96
The recognition that a number of GPCRs were activated by
very simple chemical structures derived from intermediary
metabolism considerably altered the mindset of researchers
working on aspects of metabolism and metabolic diseases. It
was now clear that molecules present in high levels could
function as homeostatic regulators via GPCR activation and
that foodstuﬀs would be likely to contain molecules that either
directly activated one or more GPCRs or did so following
conversion via intermediary metabolism. Moreover, although
substantial focus had been on chemicals with high aﬃnity for
GPCRs as being the likely endogenous regulators, this was
potentially only the case for ligands, e.g., peptide hormones, in
which substantial energy commitment was required from the
host to generate and control levels of the receptor regulator. By
contrast, as long as metabolic intermediates were present at
levels commensurate with fractional occupancy of a GPCR and
were regulated in a physiologically relevant manner then there
was every reason to assume they might act to integrate
metabolic processes via one or more orphan GPCR.
This resulted in deorphanization programs, particularly
within the pharmaceutical industry, constructing chemical
libraries of naturally occurring and endogenously produced
ligands for screening as well as the more normal synthetic
chemical libraries. Moreover, a number of deorphanization
eﬀorts turned to the use of tissue extracts,97,98 with the
prediction that unappreciated ligands for GPCRs must exist
within such extracts because of the high number of orphan
receptors. Metabolomic analysis is now a central component of
such eﬀorts. An obvious extension of these eﬀorts was that
detailed expression proﬁling was performed to attempt to
predict orphan GPCRs that might be relevant disease targets
and, therefore, worthy of signiﬁcant eﬀort to study and ﬁnd
ligands for. An obvious example of this was GPR40, the ﬁrst
deorphanized receptor for free fatty acids. This is now deﬁned
systematically as the FFA1 free fatty acid receptor.99
1.5. GPCRs Activated by Free Fatty Acids
It is now recognized that several GPCRs are activated by
various free fatty acids. This includes four receptors that have
been oﬃcially classiﬁed as members of a free fatty acid receptor
family: FFA1−FFA4.99,100 Two of these receptors, FFA1
(previously designated as GPR40) and FFA4 (previously
GPR120), are activated by MCFAs and LCFAs, while the
remaining two, FFA2 (previously GPR43) and FFA3
(previously GPR41), are activated by the SCFAs. FFA1−
FFA3 are all structurally related, sharing between 30% and 40%
sequence identity with each other and are encoded in tandem
on chromosome 19 in man.101 In contrast, FFA4 shows very
little sequence identity with the other family members. In
addition to the current FFA family members, there are several
additional GPCRs reported to be activated by free fatty acids.
GPR84 is an orphan receptor that recognizes MCFAs, while the
mouse olfactory receptor Olfr78 (OR51E2 in human) appears
to be activated by the SCFAs. Finally, although the HCA2
receptor is most commonly associated with β-hydroxybutyrate
as its endogenous agonist, the SCFA butyrate has also been
found to activate this receptor, albeit only at high
concentrations. The following sections of this review will
examine the complex pharmacology of both endogenous fatty
acids and synthetic ligands at each of these receptors focusing,
Figure 7. Constitutive activity and inverse agonism of GPCRs. In the
simplest model of activation, a GPCR can be viewed to be in
equilibrium between an inactive and an active conformation (A). In
the absence of ligand if this equilibrium favors a proportion of the
receptor adopting the active conformation, this is termed ligand-
independent “constitutive” activity. Addition of an agonist ligand shifts
this equilibrium to favor the active conformation, while an inverse
agonist shifts the equilibrium further toward the inactive conformation.
A neutral antagonist binds equally to both conformations, and thus
although able to competitively inhibit agonist signaling, it will produce
no eﬀect on its own. (B) Simulated concentration−responses for each
ligand type at a constitutively active GPCR. Assuming the inverse
agonist is competitive, increasing concentrations of inverse agonist will
both decrease the basal and right shift (i.e., requiring higher
concentrations) the potency of the endogenous agonist (C).
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in particular, on how these receptors regulate aspects of
metabolism and inﬂammation.
2. FFA1
FFA1 was the ﬁrst GPCR to be deorphanized as being activated
by free fatty acids. Initially reported simply as an uncharac-
terized 7-TMD sequence, located in man at chromosome
19q13.1,101 three separate studies in 2003 all demonstrated that
the receptor was activated by MCFAs and LCFAs.102−104
Clearly a member of the predominant rhodopsin-like or class A
group of GPCRs, various fatty acids with greater than 6 carbon
chain length caused elevations in intracellular [Ca2+] through
FFA1 and included a broad range of both saturated and
unsaturated fatty acids.102
Signals from activation of FFA1 (Figure 8) are transduced
predominantly via Gq/11-family G proteins, and the pharmaco-
logical Gq/11 inhibitor YM-254890
105 has been used in several
studies to conﬁrm this observation.106−109 Recently, a second,
closely related depsipeptide Gq/11 inhibitor, FR900359, has also
been used to conﬁrm such observations.110 Although less
common, some level of Gi-mediated FFA1 coupling has also
been described for FFA1.103,104 This may be dependent on the
speciﬁc cell type involved, with Gi-coupling particularly
reported in several breast cancer cell lines111,112 and in
keratinocytes.113 A limited number of studies have also
suggested Gs signaling through FFA1.
114,115 Finally, although
G protein-independent signaling has not been described
extensively for FFA1, arrestin-2 and arrestin-3 (also known as
β-arrestins 1 and 2) recruitment to this receptor has been
demonstrated,116−118 and there are some initial indications that
this might play a role in G protein-independent FFA1 signaling
for certain ligands.116
2.1. Expression of FFA1
Early studies on FFA1 quickly identiﬁed pancreatic islets and, in
particular, the β-cells as having particularly high levels of the
receptor,102−104,119 while subsequent studies have also found
FFA1 expression in the α cells of the islets.120−122 FFA1 is
expressed by various enteroendocrine cell types, including the L
cells that secrete glucagon like peptide-1 (GLP-1) and peptide
hormone YY (PYY),123 the I cells that secrete cholecystokinin
(CCK),124,125 and the K cells that secrete gastric inhibitory
peptide (GIP).126 Additional tissues with reported FFA1
expression include skeletal muscle, heart, liver, bone, brain,
and monocytes,102,104,127 although the functional roles of FFA1
in most of these tissues have received less attention. A number
of studies on potential roles of FFA1 in the brain on pain
perception, neurodevelopment, and neurogenesis have been
carried out, and although they are outside of the scope of the
current article interested readers should consult128 for more
details.
2.2. LCFAs at FFA1
In the initial studies that deorphanized FFA1 a wide range of
individual MCFAs and LCFAs were shown to activate the
receptor.102−104 Although each study found many diﬀerent
individual fatty acids produced eﬀects at FFA1, all displayed
modest potency, with EC50 values all greater than 1 μM. There
was also relatively little discernible structure−activity relation-
ship (SAR) apparent when comparing the activity of the various
fatty acids, and indeed, each study found a diﬀerent fatty acid or
related molecule to be the most potent: 5,8,11-eicosatriynoic
acid,102 DHA (22:6n−3),103 or stearidonic acid (18:4n−3).104
A more recent study addressed the SAR of various MCFAs and
LCFAs at FFA1 in a systematic manner,129 and a survey of this
and other studies in the area noted at least some trends in the
SAR of fatty acid ligands at FFA1.13 Notably, this included that
the long chain PUFAs typically show the highest potency at
FFA1. In addition, the activity of SFAs at FFA1 is strictly
dependent on chain length with examples shorter than 10
carbon showing little activity, while activity also drops oﬀ for
chain lengths longer than 14 carbon. Also of particular note,
several studies have indicated that the trans-unsaturated fatty
acids tend to be poor agonists at FFA1,102,103,129 which may be
of particular interest given that the trans-fatty acids are often
reported to be detrimental to health.9,24
2.2.1. LCFAs, FFA1, and Pancreatic Islets. As the initial
studies on FFA1 identiﬁed high-level expression of the receptor
in pancreatic islets and particularly the insulin secreting β-
cells,102,103 the majority of studies examining biological eﬀects
of LCFAs mediated by FFA1 have focused on this tissue.
LCFAs have diverse eﬀects on pancreatic islets. Most notably,
while acute LCFA treatment enhances glucose-dependent
insulin secretion (GSIS), chronic exposure to LCFAs inhibits
insulin secretion through lipotoxicity and associated loss of β-
cell mass. A role for FFA1 in LCFA-mediated enhancement of
GSIS was quickly established,102,103 and this has been
conﬁrmed in many studies utilizing combinations of in vitro
and in vivo models of β-cell function with pharmacological
inhibition of FFA1 or receptor knockdown or knockout
approaches.103,107,109,130−133 Mechanistic studies have indicated
that the FFA1-mediated eﬀect on GSIS is through a Gq/11-
phospholipase C pathway,106,109 leading to phosphorylation of
protein kinase D and modulation of intracellular granule
transport.134 It is important to keep in mind, however, that
although a role for FFA1 in LCFA-mediated enhancement of
GSIS is now very well accepted, FFA1 appears to contribute
only some 50% of the total eﬀect of LCFAs on GSIS.109
By contrast, a potential involvement of FFA1 in the chronic
lipotoxic eﬀects of LCFAs on β-cells has been much more
contentious.2,135,136 Despite early work suggesting FFA1 did
contribute to LCFA-mediated lipotoxicity,137 the vast majority
of subsequent studies has found these eﬀects are independent
of FFA1.109,121,131 Indeed, some studies have even indicated
that FFA1 activation may in fact be protective against
lipotoxicity and β-cell death.138,139 Although the current
consensus appears to be that FFA1 is not responsible for the
Figure 8. Signaling pathways and their associated biological outcomes
for the FFA1 receptor.
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detrimental chronic eﬀects of LCFA exposure, recent studies
have continued to suggest FFA1 may play some role in
lipotoxic eﬀects of LCFAs.140−142 One possible explanation
could be, given the diversity of LCFAs known to activate FFA1,
that eﬃcacy diﬀerences reported among LCFAs,129 or perhaps
even signaling bias in their eﬀects at FFA1, could account for
these discrepancies. The concept of signaling bias in GPCRs
with multiple endogenous ligands is not unusual and, indeed,
has been widely reported within the chemokine receptor
family.143,144 Although currently no studies have directly
assessed LCFA-mediated signaling bias at FFA1, one recent
review has suggested that abnormal activation of FFA1 by
conjugated linoleic acids may account for the particularly strong
lipotoxic eﬀects of this series of LCFA.145 Clearly further work
is needed in this area to fully elucidate involvement of FFA1 in
the eﬀects of diﬀerent LCFAs on β-cells and insulin secretion.
2.2.2. LCFAs, FFA1, and Enteroendocrine Cells. Away
from the pancreas, the area that has received the most attention
for FFA1-mediated metabolic eﬀects of LCFA has been the
enteroendocrine cells of the gut. FFA1 is expressed in several
enteroendocrine cell types including L, K, and I cells and has
been directly implicated in LCFA-mediated secretion of GLP-1,
GIP, and CCK.123,124 The role of FFA1 in the gut has
contributed to the concept that FFA1 functions as a nutrient-
sensing receptor detecting dietary fats as they are converted to
fatty acids and that, therefore, it may be possible to target the
receptor to improve metabolic health through dietary
manipulations.2,13 Interestingly, however, a recent study
found that while LCFAs do stimulate GLP-1 release from the
rat small intestine, this was only observed when the LCFA was
administered via the vasculature and not when administered via
the intestinal lumen.146 Although a limited observation from a
single study, this surprising result suggests a need to absorb the
LCFA in order to produce the eﬀect on GLP-1 release. If
conﬁrmed, this is likely to have signiﬁcant implications as to
how FFA1 functions as a nutrient sensor and, indeed, if and
how it will be possible to manipulate FFA1 function through
diet.
2.3. FFA1 Ligand-Independent Constitutive Activity
In one of the early studies that deorphanized FFA1 a
measurable level of ligand-independent activation of the
receptor was described in the reporter assay used,102 and a
subsequent study conﬁrmed this ﬁnding in a [35S]GTPγS-based
assay utilizing a FFA1-Gq fusion protein.
108 However, more
detailed examination in the latter study found that the level of
apparent constitutive activity was reduced by the addition of
bovine serum albumin (BSA) to the assay.108 LCFAs are known
to bind to albumin, and it is therefore not surprising that
coaddition of BSA with LCFA prevents LCFA-mediated
signaling at FFA1.103 Taken together, in part because the
GTPγS studies were performed on membranes derived from
cells expressing FFA1, it has been suggested that the observed
high level of constitutive activity is at least consistent with the
concept that an unidentiﬁed fatty acid(s) was present in the
preparation and this acted to partially activate the receptor. The
added albumin was then able to outcompete the receptor to
bind this ligand(s).147 A later molecular modeling study
suggested that constitutive activity (or lack thereof) of FFA1
was regulated by an ionic lock formed between two glutamate
residues present in EL2 and two arginine residues within the
ligand binding region.148 Finally, a more recent study has
revisited ligand-independent activity of FFA1 in the context of
receptor internalization.117 In this work, FFA1 was shown to
undergo both ligand-dependent and -independent internal-
ization but through distinct pathways.117 Importantly, in this
study, the addition of BSA to the assay did not aﬀect the level
of constitutive FFA1 internalization, indicating that, at least in
this system, the eﬀect was not due to LCFAs present in the
assay.
2.4. Synthetic Ligands for FFA1
FFA1 is the free fatty acid-responsive GPCR that has attracted
the greatest level of interest to date in terms of therapeutic and
translational applications.149−151 It is not surprising, therefore,
that it also has the largest described and characterized group of
chemical ligands that act as either agonists or antagonists.
However, despite the early controversy around the possible role
of FFA1 in mediating lipotoxic eﬀects in β-cells raising
questions about whether agonism or antagonism would be
preferred in a therapeutic context,152 the general consensus
now strongly favors agonism as the desired mode of action in
targeting this receptor. As a result, although there are many
diﬀerent chemical series with detailed pharmacological
characterization as FFA1 agonists, only a very limited number
of compounds have been described as FFA1 antagonists.
2.4.1. FFA1 Agonists. The ﬁrst reported synthetic agonists
of FFA1 were based on an N-substituted 3-(4-aminophenyl)-
propanoic acid template.153 These compounds had many
structural similarities to the endogenous fatty acids, and 1,
subsequently designated GW9508 (Figure 9), was ﬁrst reported
within this series. Interestingly, in relation to much later
developments on whether there might be multiple ligand
binding pockets in this receptor, these studies noted that a
carboxylate was not required for agonist function, although
carboxamides were less eﬀective.153 GW9508 was characterized
subsequently in greater detail as a FFA1 agonist by Briscoe et
al. and displays good potency to activate the receptor.130
However, GW9508 was also shown to activate FFA4, although
displaying some 70-fold lower potency to do so (see section
4.5.1). Importantly, the studies of Briscoe et al. also introduced
GW1100 as the ﬁrst FFA1 antagonist.130 Over time, GW9508
and GW1100 have been by far the most widely used FFA1
ligands for both in vitro and preclinical studies. GW9508
Figure 9. FFA1 agonists (1).
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promoted GSIS from rodent MIN6 insulinoma cells, and this
was also blocked by GW1100.130
In one of the initial FFA1 deorphanization studies the
peroxisome proliferator−activated receptor-γ (PPARγ) agonist
and antidiabetic thiazolidinedione drug, rosiglitazone (2), and
the related molecule MCC-555 (3; netoglitazone) were noted
to activate FFA1,104 and this was later extended to the related
thiazolidinedione molecules: troglitazone (4)108 and both
pioglitazone (5) and ciglitazone (6) (Figure 9).154 Indeed,
several studies have now implicated FFA1 in various biological
eﬀects of the thiazolidinediones, including proliferation of
bronchial epithelial cells,155 apoptosis in osteocytes,156 and
diﬀerentiation of osteoblasts.157 Adding a level of complexity to
the situation, the thiazolidinediones also regulate the expression
level of FFA1 through their actions at PPARγ.158 Indeed,
although studies have found FFA1 to play a role in
thiazolidinedione eﬀects on β-cell survival and insulin secretion,
these eﬀects appear to result from PPARγ-mediated alterations
in FFA1 expression rather than direct eﬀects on FFA1
itself.158,159 Moreover, a recent study demonstrated that eﬀects
of rosiglitazone to upregulate gene targets through PPARγ
involved an initial activation of FFA1, suggesting a complex,
dual-receptor signaling pathway between PPARγ and FFA1.160
While these ﬁndings suggest a complex pharmacology of the
thiazolidinediones, it must be noted that the potency of these
ligands at FFA1 is rather modest and potentially at the limits of
clinically relevant concentrations.154 Therefore, it seems
unlikely that signiﬁcant elements of the clinical eﬃcacy of
these drugs in diabetes reﬂect direct activation of FFA1.
In eﬀorts to identify novel FFA1 synthetic agonists,
derivatives of the thiazolidinedione core have been identiﬁed
that bind to and activate FFA1 but lack activity at PPARγ.161
One key example of these, 7 (Figure 9), was able to enhance
GSIS from islets isolated from wild-type mice but not from
those lacking FFA1.161 The compound also reduced blood
glucose excursion in in vivo glucose tolerance tests (GTT) in
wild-type but not FFA1−/− mice. Further variations on this core
have also been reported to display FFA1 agonism, although
none were found to have signiﬁcantly better potency than 7.162
As mentioned earlier, even though a handful of thiazolidi-
nediones with activity on FFA1 were reported concomitantly
with the deorphanization of the receptor,104 the ﬁrst potent
FFA1 agonists to appear in the literature were the fatty acid
mimicking series represented by GW9508.102,153 Soon there-
after, Song et al. disclosed a 3-aryl-3-(4-alkoxyphenyl)propionic
acid series identiﬁed in a high-throughput screening campaign
conducted by Johnson & Johnson with 8 (Figure 10) as the
most potent representative.163 By the use of an NMR-based
method for GPCR screening, Bartoschek and co-workers were
able to identify novel submicromolar FFA1 agonists such as
9.164 Using free fatty acids as the starting point and inspiration
from the early thiazolidinediones in the design of small drug-
like free fatty acid-mimicking compounds, Christiansen et al.
identiﬁed a phenoxyacetic acid hit containing a central alkyne
that was optimized to the potent and selective TUG-424 (10),
which was conﬁrmed to enhance insulin secretion at high but
not low glucose levels in a FFA1-dependent manner.165 This
compound, however, displayed lower than ideal in vitro
metabolic stability and short plasma half-life, suspected to
reﬂect metabolism of the ortho-methyl group and/or beta-
oxidation. To address these issues, focus was placed on
lowering the lipophilicity of the compounds while preserving or
increasing potency. Replacement of the terminal benzene ring
by nitrogen-containing heterocycles led to structures such as
TUG-499 (11).166 Replacement of the central ring by pyridine
resulted in similar eﬀects on potency and lipophilicity as for the
terminal position.166 Appending polar substituents resulted in
the signiﬁcantly less lipophilic and more polar compound
TUG-488 (12).167 Investigations of their ability to permeate
mucus producing membranes indicated better penetration for
10 and 12 than for 11.168 Indeed, both 10 and 12 appear to be
fully bioavailable in mice.167 Further optimization led to TUG-
770 (13), a highly potent agonist with lipophilicity in the ideal
range that exhibited robust lowering of plasma glucose in
rodents, an eﬀect that was fully preserved after 1 month of
chronic treatment.166
Structure−activity relationship exploration around other hits
from the process above combined with the simultaneously
published GW9508 series resulted in the observations that
methyleneoxy was a preferred central linker for small western
substituents whereas methyleneamino was preferred for larger
compounds and led to the identiﬁcation of TUG-469 (14,
Figure 11) as a potent FFA1 agonist with ability to enhance
insulin secretion in a glucose concentration-dependent
fashion.169 The compound was subsequently shown to protect
the rodent insulinoma-derived cell line INS-1E against
palmitate-induced toxicity through activation of FFA1.139
Since high lipophilicity was recognized as a potential problem
for TUG-469, combination with the hydrophilic 3-mesylpro-
poxy appendage of the simultaneously disclosed TAK-875 (15)
was explored and resulted in TUG-905 (16), an agonist with
low lipophilicity and high potency on both human and murine
FFA1 orthologs.170
Takeda pioneered understanding of the FFA1 ﬁeld by
discovering the potential of this receptor to enhance insulin
secretion in a glucose-dependent fashion103 and was also the
ﬁrst company to initiate clinical development and trials with a
selective FFA1 agonist. The clinical candidate TAK-875 (15)
was disclosed in 2010.171 Originally inspired by free fatty acids,
the bicyclic system was installed to resolve issues related to β-
oxidation of the 3-phenylproponic acid moiety, leading to
investigation of bicyclic systems that could block beta-oxidation
and the identiﬁcation of the dihydrobenzofurane-3-acetic acid
moiety such as in 17.171−173 With the high lipophilicity of the
Figure 10. FFA1 agonists (2).
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compound series representing an obvious problem for a clinical
candidate molecule, hydrophilic moieties were attached in the
para position of the biphenyl system that allowed accom-
modation of diverse modiﬁcations. This lead to structures with
improved properties such as 18 and TAK-875 (Figure 11).172
The structure of TAK-875 has inﬂuenced the development
programs in several companies. For example, Astellas disclosed
the relatively close TAK-875 analog 19 and demonstrated its
ability to also reduce plasma glucose and increase insulin
levels.174 Moreover, this compound has been reported to act
synergistically with the dipeptidyl peptidase-4 inhibitor and
clinically approved drug sitagliptin to normalize glucose and
increase insulin and GLP-1 levels, although the compound did
not induce GLP-1 secretion when used alone.174 Other
companies, including Piramal and Hengrui, have also developed
FFA1 agonists based on TAK-875, for example, 20 and
21,175,176 while additional structural scaﬀolds including those of
22, 23, and 24 have also recently been reported (Figure
11).177−179
TAK-875 has undoubtedly had the greatest impact in
understanding the therapeutic potential for FFA1 in the
treatment of type 2 diabetics.171 Experiments carried out in
vitro using TAK-875 (subsequently designated as Fasiglifam)
found this molecule was able to acutely enhance GSIS through
FFA1,180,181 importantly without the detrimental chronic
eﬀects that are observed with the LCFAs themselves.140,180
Interestingly, TAK-875 does not appear able to reproduce the
FFA1-mediated eﬀects on gut hormone secretion reported for
LCFAs.115,182 Regardless, TAK-875 is orally bioavailable, and in
vivo studies found TAK-875 to improve glucose tolerance in
healthy rats171 as well as to improve hyperglycemia in type 2
diabetic rats.180 On this basis, TAK-875 progressed into clinical
trials as an antihypoglycaemic/antidiabetic treatment. After
passing initial safety trials,183,184 the compound proceeded into
phase II and, indeed, III trials. Unfortunately, these trials were
terminated because of potential liver toxicity,185,186 but both the
phase II data187,188 and the initial results of the phase III studies
demonstrated clear beneﬁcial eﬀects of TAK-875 on glycaemia
and HbA1c levels in diabetic patients while appearing to reduce
the risk of hypoglycemia.185 Given that FFA1 is not expressed
highly in the liver, the current consensus is that the failure of
TAK-875 is most likely a speciﬁc compound issue and not a
target issue. Indeed, a recent study indicates that TAK-875 can
inhibit hepatobiliary transporters and suggested that this oﬀ-
target eﬀect of TAK-875 in the liver may account for its
withdrawal from clinical trials.189 Considering this and that all
in vivo studies in mice and clinical studies in man have
routinely demonstrated a capacity for FFA1 agonists to regulate
Figure 11. Synthetic FFA1 agonists (3).
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glucose homeostasis, there is every expectation that further
trials of other FFA1 agonists will take place.
2.4.2. Mode(s) of Agonist Interaction with FFA1. Initial
eﬀorts to predict the mode of agonist ligand binding to FFA1
were based on a homology model constructed from the
available X-ray structure of bovine rhodopsin.190,191 These
studies identiﬁed a group of key residues, Arg1835.39, Arg2587.35,
and Asn2446.55 (Ballesteros and Weinstein numbering in
superscript192), near the top of the TMD helical bundle that
were predicted to coordinate the carboxylate present in both
linoleic acid (18:2n−6) and GW9508. Alanine mutations of
these residues signiﬁcantly reduced GW9508 and, to a
signiﬁcantly lesser degree, linoleic acid potency at FFA1, thus
appearing to conﬁrm their predicted role in ligand binding.190
Although appreciated from early studies not to be a
requirement for FFA1 agonism153 the vast majority of synthetic
FFA1 agonists contain a similar carboxylate175,193 and thus have
typically been predicted to form such interactions. A notable
early exception to this was the thiazolidinediones ligands.
However, as these ligands also lost potency at alanine
mutations of Arg1835.39, Arg2587.35, and Asn2446.55 it was
conﬁrmed that the thiazolidinedione moiety acted as a
carboxylic acid bioisostere and maintained a similar mode of
interaction to other FFA1 agonists.154 The recent publication of
an atomic level X-ray structure for a thermally stabilized form of
FFA1 interacting with TAK-875 has further conﬁrmed the
importance of these three residues.194 However, in the crystal
structure it was only Arg1835.39 and Arg2587.35 that directly
interacted with the carboxylate of TAK-875, whereas Asn2446.55
formed a hydrogen-bond interaction with Arg2587.35 that acted
to position this residue within the binding pocket.194
While the FFA1 crystal structure demonstrated that the early
homology models predicted interactions between the ligand
carboxylate and receptor relatively well, predictions from these
models of the mode of interaction for the rest of the molecule
proved to be far from correct (Figure 12). Although the
homology models had docked FFA1 agonists within the classic
GPCR binding pocket within the TMD core of the receptor,
remarkably in the crystal structure much of TAK-875 protruded
outside the core GPCR helical structure and presumably into
the lipid environment of the plasma membrane.194 In particular,
this occurred through a gap between TMIII and TMIV of the
receptor. A similar gap was observed in the crystal structure of
another lipid-binding GPCR, the S1P-1 receptor, although in
this case it was between TMVII and TMI and predicted to
provide ligand access to a binding pocket that remained within
the central TM core.195 The implications of the unique mode of
TAK-875 binding revealed in the FFA1 crystal structure on the
basis for binding of other FFA1 ligands are not fully clear.
However, at least one recent modeling study has examined the
binding of several key ligands to a model based on the FFA1
crystal structure.196 This work found that most of the FFA1
ligands assessed could adopt a binding pose similar to TAK-
875, extending into the space between TMIII and TMIV, but
that they could also potentially adopt an alternate binding pose
where they extended into a gap between TMIV and TMV.196
A further surprising feature of agonist ligand interactions
with FFA1 that has developed is the recent view that FFA1
appears to have multiple, allosteric binding pockets.197 Given
that most synthetic FFA1 agonists contain a carboxylate head
and an extended hydrophobic tail, these typically have been
viewed as akin to synthetic fatty acids (see earlier). It was,
therefore, assumed routinely if not always directly tested that
these ligands would all interact with FFA1 in a similar manner,
with the carboxylate anchored to Arg1835.39 and Arg2587.35.
This, however, now requires reassessment. In large part this is
based on a study using the FFA1 agonist AMG 837 (25; Figure
13).197,198 This study ﬁrst noted that AMG-837 displayed
reduced eﬃcacy at FFA1 compared with the PUFA DHA as
well as two other FFA1 synthetic agonists, AM 8182 (26) and
AM 1638 (27). Surprisingly, when competition binding
experiments were conducted using [3H]AMG 837 it was
found that AM 1638 enhanced rather than decreased
[3H]AMG 837 binding, while DHA and AM 8182 decreased
[3H]AMG 837 binding but in a manner that was not consistent
with a competitive interaction.197 Such observations are clearly
incompatible with a model where each of these ligands binds to
the same site on FFA1. Furthermore, binding of [3H]AM 1638
was increased substantially and in a concentration-dependent
fashion by addition of both AMG 837 and DHA.197 Various
cooperative eﬀects, consistent with positive allosteric modu-
lation, between AM-1638, AMG-837, and DHA, were also
observed in functional studies (Figure 13).197 Finally, when
speciﬁcally assessing AMG 837, AM 1638, AM 8182, and DHA
at R183A5.39 and R258A7.35 FFA1 mutants it was apparent that
although activity of AMG-837 was completely lost at these
mutants some activity remained for DHA and AM 8182, while
the activity of AM-1638 was largely unaﬀected.197 Together,
Figure 12. Unique binding pose of TAK-875 revealed in a FFA1 crystal structure. The cocrystal structure of TAK-875 bound to FFA1 revealed that
TAK-875 extends out of the central binding pocket between TMIII and TMIV and into the cell membrane (A).190 Top (B) and side (C) views of
the TAK-875 binding pocket. Key residues in FFA1 involved in coordinating the carboxylate of TAK-875 are shown and marked in red, while the
surface of the binding pocket is marked in green.
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these data suggest a very complex picture of ligand binding to
FFA1 and that this receptor must have at least three relatively
similar binding sites.
A key implication of the demonstration that similar ligands
must bind to distinct sites on FFA1 is that it became unclear
which binding site many of the previously described synthetic
agonists, including TAK-875, actually interact with. Through a
combination of functional and competition binding experi-
ments, it is now apparent that TAK-875 and perhaps most
other reported synthetic compounds interact with the same
binding site as AMG 837.115 This suggests TAK 875 is in fact
an allosteric agonist of FFA1, and studies have now
demonstrated positive allosteric modulation of LCFA responses
at FFA1 by TAK-875.199 Xiong et al. extended this concept
further to suggest that positive allosteric modulation between
synthetic and endogenous agonists might contribute to the
therapeutic beneﬁt of these compounds in improving
postprandial glucose homeostasis.200 Attempts to model the
mode of binding of ligands that appear to bind to distinct sites
have generated mixed results as, typically, most synthetic
ligands appear able to dock into the same TAK-875 binding site
identiﬁed in the crystal structure.115 However, a recent
molecular modeling study found that the more bulky AM
1638 did not ﬁt into this site and, indeed, did not form
interactions with the key Arg1835.39 and Arg2587.35 residues.196
Instead, it was suggested that this molecule might interact at a
distinct allosteric site anchored by the positively charged
Lys622.60 residue. However, this prediction has not yet been
tested experimentally. Although the evidence now strongly
points to multiple binding sites within FFA1, many issues
remain to be answered on this topic. Most importantly, it
remains unclear where the MCFAs and LCFAs, which are
presumably the endogenous ligands of FFA1, bind to this
receptor.
2.4.3. Partial Agonism and Ligand Bias at FFA1.
Connecting, at least partially, to the observation that diﬀerent
ligands bind to diﬀerent sites on FFA1 is the question of
whether diﬀerent ligands are able to produce diﬀerent signaling
responses via FFA1. First, relating to this is the understanding
that various synthetic agonist ligands at FFA1 display markedly
diﬀerent levels of eﬃcacy.182,197,201 This may seem obvious, but
reliance in many studies on assessing ligand potency and
eﬃcacy in transfected cell lines that probably express markedly
higher levels of the receptor than native tissues can result in
both overestimates of likely ligand potency and eﬃcacy in
native tissues (due to the presence of receptor reserve). It was
thus important that the studies of Brown et al. highlighted that
although AMG 837 appeared to have high eﬃcacy, akin to the
n−3 fatty acid DHA in cells expressing high levels of the
receptor, in cells with substantially lower levels of the receptor
AMG 837 displayed only modest, partial agonism, compared to
DHA.201 By comparison, AM 1638 displayed full agonism and
was more eﬀective in regulating blood glucose and insulin levels
than AMG 837.201 In an extension to these studies, Luo et al.
showed that full agonists, such as AM 1638, are more
eﬃcacious in promoting secretion of the incretins GLP-1 and
GIP from mouse intestinal enteroendocrine cells as well as
promoting insulin secretion from both mouse and human
islets.182 Importantly, these observations were extended to in
vivo studies where robust eﬀects on GLP-1, GIP, and insulin
levels were seen only with the full agonist AM 1638.182 The fact
that full vs partial agonism of FFA1 also correlates with the
speciﬁc binding site on FFA1 the ligand interacts with197 may
suggest that activation of FFA1 through distinct binding sites
could lead to diﬀerent active conformations of the receptor and
potentially result in signalling bias. Hauge et al. were the ﬁrst to
directly assess this when they demonstrated that full agonist
ligands such as AM 1638, which bind to distinct sites from
TAK-875 and AMG 837, are able to engage and transduce
signals via both Gs as well as Gq/11-family G proteins.
115 By
contrast, TAK-875, AMG 837, and the LCFAs engaged only
Gq-mediated signaling pathways.
115 Whether this is truly a
reﬂection of receptor bias through unique active signaling
conformations or simply an issue of eﬃcacy remains to be
established. It is also noteworthy that alongside potential bias in
G protein activation proﬁles, certain ligands may also display
bias between G protein and arrestin-mediated signaling
pathways. In the case of FFA1, a recent study reported that
TAK-875 was more eﬀective than several LCFAs in recruiting
arrestin 2 and arrestin 3 to the receptor, whereas the LCFAs
were more eﬃcacious than TAK-875 in a Gq/11-dependent Ca
2+
assay.116 Moreover, this may have functional and therapeutic
consequences because although the insulinotropic activity of
the LCFAs was ablated by pharmacological inhibition of Gq/11,
the insulinotropic eﬀect of TAK-875 was reduced in islets from
arrestin 3−/− mice.116
2.4.4. FFA1 Antagonists. The FFA1 antagonist GW1100
(28, Figure 14) has been a key tool compound used extensively
in in vitro eﬀorts to explore the biology of this
Figure 13. Evidence of allosterism among structurally related FFA1
agonists. (A) Chemical structures of the three key compounds used to
demonstrate multiple allosteric binding sites on FFA1.193 When tested
in functional experiments, all three compounds were agonists,
although while AM 8182 and AM 1638 were full agonists, AMG
837 was only a partial agonist (simulated data shown in B). Despite
similar chemical structures, when tested in a competition binding assay
using [3H]AMG 837, AM 8182 was unable to fully displace [3H]AMG
837 while AM 1638 enhanced [3H]AMG 837 binding (simulated data
shown in C). Such observations are inconsistent with competitive
binding for these compounds. Functional experiments showed that the
AM 1638 concentration response is shifted to the left by AMG-837
(simulated data in D, eﬀect on AM 1638 potency shown by dashed
line), indicative of allosteric modulation.
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receptor.108,130,202−204 However, use in vivo has been much
more limited, mostly restricted to studies assessing roles of
FFA1 in the CNS where either intrathecal or intracerebroven-
tricular delivery has been used.205−207 In addition to GW1100,
several other FFA1 antagonists have been described (Figure
14). The ﬁrst of these, 29, was identiﬁed through virtual
screening of FFA1 homology models and was a ligand where
the carboxylic acid headgroup present in all FFA1 agonists
known at that time was replaced with a nitro group.208
Although informative, the IC50 of this compound was >1 μM,
and therefore, it has not found use in further studies. More
recent FFA1 antagonist ligands have included sulfonamide
derivatives such as DC260126 (30),209 which has been
reported to improve insulin sensitivity but not glucose handling
in Zuker rats210 and to protect pancreatic β-cells from apoptosis
in diabetic mice.211 A further 1,2,3,4-tetrahydroisoquinolin-1-
one FFA1 antagonist series, originally generated by Pﬁzer and
including, for example, 31,212 has also received some attention
in characterizing FFA1 function. In particular, a representative
molecule from this series, 32, has been used to demonstrate the
FFA1 dependence of insulin release by conjugated linoleic
acids213 as well as to examine the role of FFA1 in
lipotoxicity.139 Kristinson et al. identiﬁed the pyrimidinylhy-
drazone ANT-203 (33) in a high-throughput screen and
demonstrated the usefulness of the compound in studies with
isolated islets and pancreatic-derived cell lines.140 Waring et al.
described a related series of 2-(pyridinyl)pyrimidines, exempli-
ﬁed by 34, as antagonists of FFA1 capable of reducing overload
of β-cells (Figure 14).214 Little has been done to detail the
pharmacology of the FFA1 antagonists and how their binding
might be related to the multiple agonist binding sites noted to
be present in the receptor. In the initial study identifying
GW1100, this ligand produced antagonism of GW9508 that
would not be considered consistent with competitive
antagonism, while the ﬁrst study reporting ANT-203 suggested,
in passing, that this compound was competitive with elaidic
acid.140 Unlike the situation with antagonists of FFA2 (see
section 3.5.2), the FFA1 antagonists described have typically
been found to function across species, albeit with substantially
diﬀerent IC50’s.
215 This indicates that considerable care should
be taken when selecting an appropriate antagonist and eﬀective
concentration to use in studies on FFA1 in nonhuman cells and
tissues.
2.4.5. FFA1 Fluorescent Tracers. In recent times,
ﬂuorescently labeled GPCR ligands have proven to be
extremely useful tools to visualize and quantify ligand binding
to GPCRs in real time.216 In the case of FFA1, very early eﬀorts
were made to generate ﬂuorescent ligands for this receptor by
incorporating a bodipy ﬂuorophore into a saturated fatty acid,
35 (Figure 15).217 Although this approach was moderately
successful and used in a ﬂow cytometry-based assay to assess
the aﬃnity of various LCFAs, the low aﬃnity and high
lipophilicity of 35 signiﬁcantly limited its utility. More recently,
based largely on insights gained through the TAK-875/FFA1
cocrystal structure, signiﬁcantly higher aﬃnity FFA1 ﬂuorescent
ligands have been described based on either TAK-875 (36 and
37)218,219 or TUG-905 (38).220 Although these ligands display
high aﬃnity, they remain highly lipophilic or amphiphilic,
which has made quantifying and/or visualizing their binding by
conventional ﬂuorescence methodologies challenging. To
overcome this, Bertrand et al. utilized an approach in which
cells were ﬁrst labeled with 37 and then the signal was boosted
using an antibody directed against the Alexa488 ﬂuorophore
present in 37.218 By contrast, Christiansen et al. developed a
bioluminescence resonance energy transfer (BRET)-based
assay using 38.220 For this, the small, bright, Nanoluciferase,
which can serve as an energy donor to the 4-amino-7-
nitrobenzofurazan ﬂuorophore in 38, was introduced into the
N-terminal domain of FFA1. In this format the nonspeciﬁc
signal was expected to be greatly reduced, as only molecules of
Figure 14. FFA1 antagonists.
Figure 15. FFA1 ﬂuorescent ligands.
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ligand in close proximity to the Nanoluciferase-tagged receptor
are detected.221 Indeed, despite being highly lipophilic, 38
displayed high aﬃnity and very good speciﬁc to nonspeciﬁc
binding signals using the BRET assay format. Taken together, it
is likely that these and additional ﬂuorescent FFA1 ligands will
be important tools in assessing ligand interaction with this
receptor.
3. FFA2 AND FFA3
In a similar time frame as the deorphanization of FFA1, two of
the other 7-TMD sequences, GPR43 and GPR41 noted by
Sawzdargo et al. to also be located in human at chromosome
19q13.1,101 were paired with SCFAs as endogenous
ligands.222−224 Subsequent systematic nomenclature has
redeﬁned GPR43 as FFA2 and GPR41 as FFA3.225 However,
as with FFA1, the initial designations as GPR43 and GPR41
remain ﬁrmly entrenched in the literature.
Examination of the signaling pathways of FFA2 and FFA3
(Figure 16) has revealed that FFA3 couples predominantly if
not exclusively to “Gi/o”-family G proteins and hence is best
appreciated as being able to mediate inhibition of adenylyl
cyclase and reduce levels of intracellular cAMP.222−225 By
contrast, as well as interacting with “Gq/11”-family G proteins,
FFA2 is also able to transduce signals via Gq/11/G11-linked
pathways.222 Few studies have examined G protein-independ-
ent signaling of FFA2 and FFA3; however, FFA2 does recruit
arrestin-3,226,227 and at least one study has linked anti-
inﬂammatory actions of FFA2 to this pathway.228 By contrast,
FFA3 interactions with arrestins have not typically been
reported.5,136
3.1. Expression of FFA2 and FFA3
Early studies identiﬁed various immune cells as expressing both
of the SCFA receptors, with FFA2 particularly highly expressed
in monocytes and polymorphonuclear cells.222−224 Given that
the SCFAs are generated primarily in the gut through
fermentation of dietary ﬁber (Figure 2), it is perhaps not
surprising that both FFA2 and FFA3 are expressed in the gut,
primarily by the enteroendocrine cells.229−234 Expression of
both FFA2 and FFA3 has also been described in pancreatic β-
cells,235 and interest has been increasing recently in the role of
these receptors in regulating insulin secretion.236−238 Ex-
pression of both FFA2 and FFA3 in adipose tissue has also
been reported,239,240 although the expression of FFA3 has been
contentious, with many studies ﬁnding only FFA2.227,241,242
FFA3 only appears to be expressed highly in the neurons
present in both sympathetic ganglia and the enteric nervous
system.243−247 Finally, FFA2 and FFA3 expression has been
described in a number of cancers, including breast, colon, and
liver.248−250 Although few studies have assessed the function of
these receptors in cancer, there is some evidence that FFA2 in
particular has tumor-suppressive actions.248,249
3.2. GPR42
In addition to FFA1, FFA2, and FFA3, in primates there is a
fourth GPCR encoded in tandem within the same linkage
group on chromosome 19q13.1 in human.101 This GPCR,
known as GPR42, although closely related to the FFA
receptors, has received relatively little attention due to it
being described as a potential pseudogene in the original
studies of Brown et al. that deorphanized FFA2 and FFA3.222
GPR42 is most closely related to FFA3, and indeed, there are
only six amino acid variations between human FFA3 and
GPR42 (Figure 17).222 One of these is the replacement by
tryptophan of an arginine residue in FFA3 (Arg174EL2), which
appears to be integral for agonist function.222 However, Liaw
and Connolly indicated GPR42 to be markedly polymorphic,
and when over 200 GPR42 alleles were analyzed, more than
60% had arginine at this position,251 and thus were likely to
respond to SCFAs. Another recent study has further
demonstrated a number of functional GPR42 variants with
the capacity to be expressed in man.252 In this study, despite the
very similar sequences of GPR42 and FFA3, the pharmacology
Figure 16. Signaling pathways and their associated biological
outcomes for the FFA2 and FFA3 receptors.
Figure 17. Position and function of residues that diﬀer between
human GPR42 and human FFA3. A snake diagram shows the amino
acid sequence and position of residues in GPR42. Residues highlighted
are those that diﬀer between GPR42 and FFA3. When the equivalent
residues were mutated in FFA3 to match those in GPR42 those
marked in green did not aﬀect function, those in red abolished
function, those in blue increased constitutive activity, and those in
brown had only a modest eﬀect on function of the endogenous
SCFAs.212
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of the functional GPR42 variants diﬀered in terms of potency of
the SCFA propionate.252 There is also some indication of
polymorphism within the copy number for GPR42, with a
relatively high 18.5% of alleles containing a deletion of the
GPR42 sequence, while other alleles are likely to have multiple
copies.252,253 It should also be noted that as most expression
studies on FFA3 have only analyzed mRNA levels through RT-
PCR, given the sequence similarity between GPR42 and FFA3,
unless primers were designed to speciﬁcally exclude detection
of the GPR42 transcript it is likely that they would fail to
diﬀerentiate between the two. Indeed, in many studies utilizing
RT-PCR the primers used would detect both FFA3 and GPR42
expression.223,227,250 Taken together, it appears likely that
GPR42 does represent more than simply a pseudogene, but the
broader implications in terms of tissue distribution and whether
functional eﬀects of SCFAs via GPR42 are restricted to “gene-
dosage” or truly distinct pharmacology compared with FFA3
remains essentially unexplored.
3.3. SCFAs at FFA2 and FFA3
SCFAs with chain length between C1 and C6 are agonists at
both FFA2 and FFA3. However, unlike FFA1, where there is
limited discernible SAR among the various LCFAs, clear trends
based on carbon chain length can be observed in relation to the
potency of SCFAs at these receptors.99,136 In the case of FFA2,
by incorporating data from multiple studies a general consensus
for the rank order of potency at the human receptor of C2 ≈
C3 ≈ C4 > C5 > C6 ≈ C1 has been established.136,254 In
contrast, the rank order established for human FFA3 is C3 ≈
C4 ≈ C5 > C6 > C2 > C1. Importantly, these diﬀerences in
rank order of agonist potency between FFA2 and FFA3 mean
that certain SCFAs show greater potency at one receptor over
the other. Most notably C2 is consistently reported to be
approximately 10 times more potent at human FFA2 across
multiple assay end points.223,255 This has resulted in some
researchers using C2 as a selective activator of FFA2.234,242
Despite the relatively modest potency diﬀerence for C2
between these two receptors, this can have value when
combined with selective knockout or knockdown of one or
other of the receptors, particularly because the range and
availability of high-aﬃnity selective ligands for these two
GPCRs remains limited (see sections 3.4 and 3.5). However,
further issues exist in terms of using the SCFAs as selective
agonists for FFA2 or FFA3 when employing rodent models and
cell lines derived from rodents. Hudson et al. demonstrated
substantial diﬀerences in SCFA potency and selectivity between
species orthologs of these receptors.256 Thus, while conﬁrming
the higher potency of C2 for human FFA2 than FFA3, this
SCFA was shown to be equipotent at the mouse orthologs.
Moreover, although C3 is equipotent at human FFA2 and
FFA3 it is markedly selective for FFA3 over FFA2 in mouse.256
Molecular analysis showed these variations to be linked to the
extent of constitutive activity displayed by the species
orthologs, and both features could be switched by judicious
mutagenesis of residues in EL2 of the receptors.256
To establish the mode of SCFA binding to FFA2 and FFA3,
Stoddart et al. aligned the sequences of FFA1, FFA2, and FFA3
and noted that the two key arginine residues implicated in
ligand binding to FFA1 at positions 5.39 and 7.35 were
conserved in both FFA2 and FFA3, while the key asparagine
residue at 6.55 was a semiconserved histidine in the two SCFA
receptors.225 When each of these three residues was mutated to
alanine in FFA2 or FFA3 a complete loss in activity for the
SCFAs was observed.225 Thus, it appears that the carboxylate of
the SCFAs interacts with the same conserved residues of FFA2
and FFA3 as have been shown to interact with the carboxylate
of TAK-875 in the FFA1 crystal structure. Recently, a more
detailed map of the mode of binding of the SCFA propionate
was generated based on a homology model constructed from
the FFA1 crystal structure. While conﬁrming the direct roles of
arginine residues 5.39 and 7.35 in coordinating the carboxylate
this model suggests that the key contribution of the histidine at
position 6.55 is to organize the binding pocket by making a
direct interaction with the arginine at 7.35 to eﬀectively
position this residue.257
Assessing the biological functions of the SCFAs at FFA2 and
FFA3 has proven particularly challenging.136 This is in large
part due to similar expression proﬁles, the very low potencies of
the SCFAs at these receptors, and the relatively similar
pharmacology between them. Together these factors have
made it highly challenging to separate FFA2 from FFA3
function based on pharmacology of the endogenous ligands.
Further complicating the issue is that expression of FFA2 has
been reported to be reduced in at least one line of FFA3−/−
mice,242 potentially hindering the interpretation of knockout
mouse studies with these receptors. Despite these challenges, a
growing number of studies have now implicated FFA2 and
FFA3 in SCFA eﬀects on both metabolism and inﬂammation.
3.3.1. SCFAs, FFA2, and FFA3 in the Gastrointestinal
Tract. As the SCFAs are generated primarily through the
fermentation of ﬁber by gut microbiota, the highest levels of
SCFAs are within the GI tract. It is, therefore, not surprising
that this is one of the tissues that has received substantial
attention in terms of the functions of the SCFA receptors. As
was the case with FFA1, the ability of FFA2 and/or FFA3 to
regulate gut hormone secretion has received particular
attention. Although many early studies had demonstrated
expression of both FFA2 and FFA3 in enteroendocrine
cells,230−233 it was the work of Tolhurst et al. that ﬁrst
established a clear functional role.234 These studies demon-
strated that C2 and C3 both stimulate GLP-1 release from
primary murine colonic cultures and that this was not blocked
by treatment of the cells with pertussis toxin, indicating a non-
Gi/o-mediated pathway. The eﬀect was lost in cultures derived
from FFA2−/− but not FFA3−/− mice, and as it was also shown
that C2 and C3 increased intracellular [Ca2+], it was concluded
that the SCFAs increased GLP-1 via a FFA2-Gq/11-mediated
pathway.234 In these studies, although it was found that GLP-1
levels and associated glycaemic control were altered in FFA2−/−
mice, it was not tested whether the SCFAs stimulated GLP-1
release in vivo. It was not until a more recent study
demonstrated that intracolonic infusion of C3 increased
secretion of both GLP-1 and PYY in vivo and that these
eﬀects were absent in FFA2−/− mice that the ability of SCFAs
to stimulate gut hormone secretion via FFA2 in vivo was
conﬁrmed.258
In addition to enteroendocrine cells, FFA2 and FFA3 are also
expressed in the stomach, and in particular, they appear to be
expressed by ghrelin-containing cells.259 Interestingly, SCFAs
regulate ghrelin secretion from ex vivo gastric tissue, but unlike
GLP-1 and PYY, C2, and C3 both appear to inhibit ghrelin
secretion.259 Pharmacological characterization indicates that
this is mediated by a Gi/o-mediated pathway, as it was blocked
by treatment with pertussis toxin, and although these cells
express both FFA2 and FFA3, tissue from knockout mice
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indicates that FFA2 is the primary receptor regulating ghrelin
secretion by SCFAs.259
3.3.2. SCFAs, FFA2, FFA3, and Adipose Tissue. The
SCFAs have long been known to have diverse eﬀects on
adipose tissue, inﬂuencing processes such as adipogenesis,
lipolysis, and leptin secretion.260 Since the identiﬁcation of
FFA2 and FFA3 as receptors for SCFAs, signiﬁcant eﬀorts have
been made to establish which eﬀects are mediated by each
receptor. Most notably, the ability of SCFAs to inhibit lipolysis
in adipocytes had long been established.260 This was quickly
linked to actions of FFA2.241,261 In the key studies of Ge et al. it
was found that C2 and C3 inhibited lipolysis in both a cell line
model (diﬀerentiated 3T3-L1 cells) and in primary murine
adipocytes and, importantly, that this eﬀect was absent in
adipocytes from FFA2−/− mice.261 As would be expected, the
pathway was linked to FFA2-Gi/o signaling as the antilipolytic
eﬀect of C2 was eliminated by pertussis toxin pretreatment.
The inﬂuence of FFA2 on adipogenesis has also been
explored. Hong et al. demonstrated that C2 and C3 SCFAs
enhance lipid content during diﬀerentiation of 3T3-L1
adipocytes.241 It was also found that FFA2 transcript expression
was substantially upregulated during the diﬀerentiation process
and that transfection with FFA2 siRNA inhibited diﬀer-
entiation.241 Together these in vitro ﬁndings suggest a role
for SCFAs and FFA2 in adipogenesis. An initial in vivo study
using FFA2−/− mice perhaps supports such a role in that the
knockout mice had reduced body fat mass when fed a high-fat
diet.262 By contrast, a study using a diﬀerent strain of FFA2−/−
mice found that these animals are obese and that mice
overexpressing FFA2 in adipose tissue are lean.263 This study
found that in vivo adipogenesis was not diﬀerent across these
transgenic mice, suggesting little role for FFA2 and SCFAs in
adipogenesis in vivo. Similarly, a study on primary human
adipocyte diﬀerentiation also found no evidence for a
relationship between SCFAs, FFA2, and adipogenesis.264 It
appears clear from these studies that there is signiﬁcant species
and strain variation in the eﬀects of the SCFAs and FFA2 in
particular on adipocyte function. As the microbiota play such a
central role in production of the SCFAs it will be of great
interest to understand how this may vary between locations and
if this might contribute to variation in experimental
observations.
The relationship between SCFAs and leptin secretion has
also resulted in some controversy.136 Notably, while an early
study suggested SCFA increased leptin secretion via activation
of FFA3,240 subsequent work has generally not found FFA3 to
be expressed in adipocytes.227,241,242 Interestingly, a study using
adipocytes from FFA3−/− mice did ﬁnd that C2 and C3 lost
their ability to stimulate leptin secretion when FFA3 was not
present.242 However, as noted earlier, the authors observed
decreased FFA2 expression in the cells from these FFA3−/−
mice, and because they were unable to detect FFA3 expression
in the wild-type adipocytes, it was concluded that most likely
FFA2, and not FFA3, mediated SCFA-stimulated leptin
secretion.242 A later study using FFA2−/− mice found that
circulating leptin levels were not aﬀected by FFA2 knockout
but, surprisingly, were decreased by adipocyte overexpression of
FFA2.263 In terms of signaling, early studies indicated that the
SCFA eﬀect on leptin secretion was eliminated by pertussis
toxin treatment, implicating a Gi/o-mediated pathway,
240 and
therefore, possibly either FFA2 and/or FFA3 could be involved.
Finally, SCFAs have also been reported to regulate glucose
uptake in adipocytes, in particular, enhancing insulin-stimulated
glucose uptake.239,265 One study has found that these eﬀects are
reduced by transfection of FFA3 siRNA, suggesting a role for
the FFA3 receptor.239 However, this study did not assess the
eﬀects of FFA2. It has, however, also been suggested in a non-
peer-reviewed patent application that FFA2 activation may
modestly stimulate glucose uptake.266 While the study on FFA3
suggested that its actions were to enhance insulin activity on
adipocytes, this is less clear for FFA2. Indeed, in vivo C2
administration was found to suppress insulin signaling in
adipocytes of wild-type but not FFA2−/− mice.263 Using
adipocytes generated from these FFA2−/− mice it was shown
that C2 inhibited insulin-stimulated glucose uptake in wild-type
but not the knockout animals and that this was blocked by
pertussis toxin treatment but not by a Gq-targeted siRNA.
263
Together, these data suggest that FFA2-Gi/o pathways inhibit
insulin signaling and glucose uptake in adipocytes. Most
interestingly, this study also indicated that this was not the case
in either muscle or liver, with the authors suggesting the
resulting shift in insulin-stimulated metabolism from adipose to
other tissues accounted for the beneﬁcial eﬀects of FFA2 on
energy utilization and metabolic homeostasis.263
3.3.3. SCFAs, FFA2, FFA3, and Insulin Secretion. Unlike
FFA1, where focus has been predominantly on function in
pancreatic islets, less work has examined potential roles of
FFA2 and FFA3 in this tissue. Although not highlighted to
express FFA2 or FFA3 in the early deorphanization studies,
both of these receptors were found in various rodent
insulinoma β-cell lines.235 Several recent studies have now
begun to assess directly roles of FFA2 and FFA3 on insulin
secretion, although they have yielded somewhat diﬀerent
results. Two studies have found that SCFAs activate FFA2 to
enhance GSIS from mouse islets both in vivo and in vitro and
that this occurs through a Gq/11-mediated pathway.
236,237 By
contrast, a separate study found instead that SCFAs inhibit
GSIS through actions at both FFA2 and FFA3 and that this
occurs through a Gi/o-mediated pathway.
238 While these results
appear to be contradictory, it has been found consistently in
mouse islets that Gq/11 pathways via FFA2 enhance while Gi/o
pathways via FFA2 and FFA3 inhibit GSIS.236−238 Therefore, it
is most likely that the diﬀerences between studies on the role of
FFA2 represent other factors, including potentially the strain of
mice used, which may inﬂuence whether FFA2-Gq/11 or -Gi/o
signaling pathways predominate. Studies on human islets,
however, have not found any eﬀect of SCFAs on GSIS, despite
the fact these ligands did activate both Gq/11 and Gi/o
signaling.237 This has been taken to suggest that in human
islets the combination of activating Gq/11 and inhibiting Gi/o
pathways results in no net change in GSIS.237 More work will
be needed to determine which factors determine whether FFA2
Gq/11 vs Gi/o signaling predominates and whether SCFAs will
stimulate vs inhibit GSIS in diﬀerent settings.
3.3.4. SCFAs, FFA2, FFA3, and Inﬂammation. Each of
the SCFAs receptors is expressed on certain immune cells.
Functionally, FFA2 appears to be important in promoting
SCFA-mediated chemotaxis of neutrophils.267−269 As might be
expected, the FFA2-chemotactic response was inhibited by
pertussis toxin treatment and thus is Gi/o mediated, presumably
via the release of βγ complexes.268A few studies have also
explored whether FFA2 regulates cytokine production with, for
example, acetate being found to inhibit secretion of tumor
necrosis factor (TNF) from mononuclear cells: an eﬀect that
was reported to be inhibited by an anti-FFA2 antibody.270 A
further study carried out on intestinal epithelial cells indicated
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that SCFAs enhance the protective secretion of cytokines and
chemokines from such cells, in this case via activation of both
FFA2 and FFA3.271
3.4. FFA2, FFA3, and the Gut Microbiota
In large part due to the very low potency of SCFAs at FFA2
and FFA3, establishing speciﬁc functions of these receptors in
vivo has been challenging. As described above, the primary
source of SCFAs in the body is through fermentation of dietary
ﬁber by the gut microbiota. There are strong links established
between the gut microbiota, health, and disease.28−31,272,273
Therefore, it is not surprising that a number of studies have
aimed to assess whether the SCFAs, acting through FFA2 and/
or FFA3, provide key links between the gut microbiota and
health. A number of experimental approaches have been
employed in this regard, but most commonly either germ-free
(GF) or antibiotic-treated mice lacking gut bacteria have been
studied in combination with exogenous SCFAs administration,
exposure to speciﬁc microbiota, and/or the use of receptor
knockout animals (Figure 18).263,267,274−278
The studies on FFA2 have demonstrated how this receptor
in particular links gut microbiota SCFA production to
inﬂammation. The studies of Maslowski et al. were the ﬁrst
in this area, demonstrating that FFA2−/− mice had dysregulated
immune responses to induced colitis and that similar
dysregulation was observed in wild-type GF mice.267
Importantly, acetate treatment ameliorated the detrimental
eﬀects of GF mice, suggesting but not proving a mechanistic
link to FFA2. The later studies of Smith et al. were able to
provide a more direct link by examining how the gut microbiota
regulate the population of regulatory T cells (TRegs) in the
intestine.276 Here, it was found that GF conditions reduced the
population of TRegs in the intestine and that SCFAs restored
these populations. Critically, Smith et al. demonstrated that the
eﬀects of SCFAs on GF mice were lacking in FFA2−/− animals,
providing strong evidence to link the gut microbiota through
SCFAs to biological functions mediated by FFA2.276 Studies
have also demonstrated that the eﬀects of gut-derived SCFAs
on inﬂammation through FFA2 extend beyond the intestine,
where, for example, IL-1β and CXCL1 production are
decreased in response to C2 and C3 in a murine model of
gout in GF, antibiotic-treated, and FFA2−/− mice. Once again,
the eﬀects of raising the mice GF were reversed by exogenous
administration of SCFAs.278 Finally, GF mice have also been
used to link the gut microbiota to the function of FFA2 in
adipose tissue, where in one study FFA2−/− mice were found to
be obese compared to wild-type mice when raised under
conventional conditions but were not diﬀerent from wild type
when raised GF.263
A number of studies have also assessed the function of FFA3
using similar approaches. Samuel et al. found that convention-
ally raised FFA3−/− mice had decreased adiposity compared to
their wild-type controls, but this was not apparent in GF
mice.275 In particular, this appeared to relate to PYY levels,
which were decreased in FFA3−/− mice when gut microbiota
were present but were not in GF mice. One study has also
linked dietary ﬁber, the microbiota, SCFAs, and FFA3 to
allergic airway disease.277 In this study a high-ﬁber diet altered
microbiota composition in both the gut and the lung, increasing
SCFA levels, and protected against allergic airway disease.
Exogenous C3 administration was found to produce similar
eﬀects to ﬁber, but such eﬀects of C3 were absent in FFA3−/−
but not FFA2−/− mice.
These studies highlight only the beginning of what is likely to
be a key area studying the endogenous functions of FFA2 and
FFA3 in coming years. While the studies using antibiotics and
Figure 18. Experimental approaches to study the links between gut microbiota and SCFAs in health and disease. Several experimental approaches
have been used to link the microbiota and the SCFAs they produce to health and disease. Most notably, mice can be raised under germ-free
conditions or treated with antibiotics to establish what eﬀects on health the microbiota have. Treating such mice with exogenous SCFAs can then be
used to determine which beneﬁcial eﬀects of the microbiota are recovered. Alternatively, mice may be exposed to speciﬁc microbes, for example,
those that produce higher levels of acetate in order to establish the importance of individual microorganisms. Finally, FFA2−/− and/or FFA3−/− mice
can be used in combination with these approaches to determine the contribution of these receptors to the biological eﬀects of the microbiota.
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GF mice are clearly informative, more work is needed to
examine how altering the makeup of the microbiota in more
subtle ways, such as altering the speciﬁc species present, aﬀects
health and disease via the SCFA receptors. This is particularly
relevant given that it is recognized that certain species of
microbiota produce higher amounts of C2 and C3 while others
will produce more C42 and that these SCFAs are known to
have diﬀerent potency at FFA2 and FFA3. Indeed, in terms of
human health this may have signiﬁcant implications, particularly
with the probiotic industry aiming to colonize the gut with
beneﬁcial bacteria.
3.5. Synthetic Ligands for FFA2
Despite initial challenges, a growing number of synthetic
ligands have now been reported for FFA2. These include
orthosteric and allosteric examples and both agonists and
antagonists. A particular challenge within this area has been
identifying compounds with good selectivity for FFA2 over
FFA3, and although this has improved in recent years, it is not
yet fully resolved. Species diﬀerences between human and
rodent orthologs of FFA2 have also proven challenging to
overcome, and particularly this relates to the pharmacology of
FFA2 antagonist ligands.
3.5.1. Orthosteric FFA2 Agonists. Initial studies high-
lighted the ability of SCFAs of varying chain length to activate
FFA2. While the potency of formic acid (C1) at FFA2 is
extremely low, the fact that it does act as an agonist indicates
that a carboxylate is all that is required to both bind and activate
this receptor. However, the limit in acceptance of aliphatic
chain length to C5−C6 suggested that the pocket for
orthosteric ligands is small and constrained. Indeed, apart
from the endogenous SCFAs, in early years the only other
orthosteric ligands reported in the primary literature to activate
FFA2 were a group of synthetic small carboxylic acids
(SCAs),255 although several useful ligand series and interesting
data on these had appeared in the patent literature.279
Chemicals within the SCA group that activated FFA2 in
preference to FFA3 included trans-2-methylcrotonic acid and
cyclopent-1-enecarboxylic acid and, in general, possessed sp2-
or sp-hybridized α-carbons. However, even though markedly
selective for FFA2 these SCAs were not more potent than the
SCFAs.255 Despite this, at least two of these sp-hybridized α
carbon SCAs, propiolic acid and 2-butynoic acid, were found to
potentiate GSIS in wild-type but not FFA2−/− mice.237
Molecular modeling has been conducted to identify potential
binding poses of the FFA2-selective SCAs and has suggested
additional residues, including Tyr903.33, Glu166EL2, Phe168EL2,
Leu1835.42, Cys1845.43, and Tyr2386.51, beyond the arginine and
histidine residues previously implicated in SCFA binding as
likely to contribute to the orthosteric binding pocket.255 Over
time the bulk of these have been mutated and analyzed for
function.227,256
One alternate approach that has been utilized to selectively
activate a speciﬁc member within a receptor family that
contains very similar orthosteric binding pockets is to modify
the receptor instead of the ligand to generate selectivity.
Typically this involves the generation of a receptor activated
solely by synthetic ligand (RASSL) or designer receptor
exclusively activated by designer drugs (DREADD) form of
the receptor, which will be activated by a synthetic ligand but
not by the receptor’s endogenous ligand(s).280,281 In order to
develop such a version of FFA2, Hudson et al. took the novel
approach of utilizing species diﬀerences in the pharmacology of
FFA2 (Figure 19).226 Given the importance of nondigestible
carbohydrates to the diet of ruminants, the activity of SCFAs at
the bovine ortholog of FFA2 was examined and indicated that
this ortholog, where C6 was the optimal chain length, had a
strong preference for longer chain lengths than human
FFA2.226 Moreover, when tested at the bovine receptor, within
the group of SCAs described by Schmidt et al.,255 a number
were markedly more potent than at human FFA2. Most notably
sorbic acid (2,4-hexadienoic acid) (Figure 19) was more than
1000-fold selective for bovine FFA2 over human.226 Molecular
modeling and mutational studies were undertaken to identify
residues that were diﬀerent in the bovine ortholog and that
could account for this eﬀect. A single C141G4.57 mutation in
human FFA2 resulted in a substantial gain in potency for sorbic
acid.226 Although this form of the receptor now responded to
sorbic acid, it maintained function for the SCFAs, and
therefore, in order for it to be useful as a RASSL/DREADD
it was critical to further mutate the receptor to eliminate SCFA
binding. Alteration of His2426.55 to glutamine achieved this,
resulting in a form of the receptor that still displayed strong
responsiveness to sorbic acid but now with virtually no
response to any endogenous SCFA.226 Interestingly, earlier
studies had indicated that mutation of this residue to alanine
allowed a level of activation of human FFA2 by both caproic
acid (C6) and even caprylic (C8).225 Importantly, as FFA2 can
interact with both Gi/o and Gq/11-family G proteins, the
modiﬁed receptor showed good responses to sorbic acid across
the full range of assays usually employed to assess FFA2
signaling, including inhibition of forskolin-stimulated cAMP
levels, elevation of intracellular [Ca2+], phosphorylation of
ERK1/2, and global cellular changes assessed through dynamic
mass redistribution.226 This suggests that this RASSL/
DREADD version, if incorporated into a knock-in animal in
which this form replaces the wild-type receptor, could be a
powerful tool to dissociate FFA2 from FFA3-mediated
Figure 19. Characteristics of an FFA2-DREADD. A designer receptor
exclusively activated by designer drugs (DREADD) form of FFA2 was
generated based on species diﬀerences between the bovine and the
human orthologs of this receptor, where two mutations were
incorporated, one in TMV and the other in TMVI.216 At wild-type
FFA2 C3 but not sorbic acid activates the receptor to stimulate various
downstream signaling pathways. In contrast, at the DREADD, C3 has
no eﬀect while sorbic acid is able to activate equivalent pathways to
those activated by C3 at wild-type FFA2.
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biological eﬀects in vivo. This idea has recently been discussed
further by Bolognini et al.282
Given the interest in the contribution of SCFAs and the
microbiota to health and disease noted earlier273,283,284 there is
a remarkable paucity of larger and more potent synthetic FFA2
orthosteric agonists described to date. Indeed, only a few series
of chemical ligands with these features have been reported in
the primary scientiﬁc literature.279 Of these, a series of
compounds based on a 4-oxobutanoic acid backbone is best
characterized in terms of their basic pharmacology. On the basis
of an international patent application266 Hudson et al.
synthesized 39 and the related 40 (Figure 20) and
demonstrated that they were both able to activate human
FFA2 with submicromolar potency and were highly selective
over FFA3 as well as the other free fatty acid receptors.227
These compounds were clearly orthosteric in action because,
like the SCFAs and SCAs, agonist function was lacking at
R180A5.39, R255A7.35, and H242A6.55 mutants of FFA2.
Moreover, the carboxylate moiety of these compounds was
also integral to function as methyl and tert-butylesters of 40
were found to be inactive.227 Modeling of the potential mode of
binding of 39 into the FFA2 homology model described by
Sergeev et al. illustrated interactions with not only the key
orthosteric residues that bind the SCFA but also with further
residues including tyrosine 3.33, valine 5.38, tyrosine 6.51, as
well as a further tyrosine in EL2.257 Each of these residues had
previously been shown to be likely to contribute to interaction
with this ligand as mutation of each reduced the potency of
39.227
Perhaps as might be generally expected for an orthosteric
ligand, FFA2 signaling elicited by 39 was very similar to that by
the SCFA C3, as assessed across multiple signaling end
points.227 Interestingly, a recent study by Brown et al.
generated four additional FFA2 agonists from this chemical
series, 41−44 (Figure 20), ﬁnding markedly diﬀerent signaling
responses among them.285 Notably, while each of these
compounds acted as a potent agonist in a [35S]GTPγS assay,
only 41 and 44 showed equivalent FFA2 agonism in a cAMP
assay, while 42, 43, and 44 all appeared rather to act as inverse
agonists in a yeast-based assay designed to assess Gi coupling to
FFA2.285 These diﬀerences perhaps suggest some level of bias
in the actions of these compounds at FFA2. GPCR signaling
bias is often associated with bitopic ligands that interact with
the orthosteric site as well as additional allosteric sites outside
of the orthosteric binding pocket, and Brown et al. considered
whether this might be the case for this series of ligands.
Although these studies did not ﬁnd clear support for a bitopic
mode of action within this series,285 it should be noted that,
given the very small size of the SCFAs, which display very high
ligand eﬃciency, any synthetic agonist with markedly higher
potency will be required to extend outside the direct binding
pocket of the SCFAs. Indeed, this means that such synthetic
agonist ligands must make additional contacts with FFA2
compared to the SCFAs. Whether this results in “bitopic-like”
properties of such synthetic compounds will need to be more
fully addressed in the future.
Synthetic agonists from this series have also now been used
to conﬁrm several of the biological functions of this receptor in
vitro. Both Hudson et al. and Brown et al. conﬁrmed FFA2-
mediated secretion of GLP-1 and inhibition of lipolysis using
these compounds.227,285 Brown et al. also demonstrated that
the compounds elicited a Ca2+ response in neutrophils.
Importantly, the eﬀects on lipolysis were absent in adipocytes
from FFA2−/− mice,285 conﬁrming that the ligand eﬀects were
via FFA2. Finally, within this series, Hudson et al. also noted
some species variation in activity ﬁnding, in particular, that
although 39 was active at both human and mouse FFA2, 40
appeared to act as a potent agonist only at the human
ortholog.227 This indicates that considerable care must be taken
when selecting compounds from this series for in vivo or other
rodent-based studies.
In addition to representatives from the chemical series
discussed above a recent study has employed an example from a
separate chemical series of FFA2 agonists that was also
described initially in the patent literature.286 Forbes et al.
synthesized 45 (Figure 20), demonstrated it to be a potent and
selective FFA2 agonist, and assessed the in vivo pharmacology
of this compound.287 Although the molecular basis for
interaction of 45 with FFA2 was not assessed in detail, given
that it contains a carboxylate and was not allosterically
modulated by C2,287 this compound is likely to be an
orthosteric FFA2 agonist. Testing the compound in vivo
demonstrated that it stimulated GLP-1 secretion, but this was
only detected when the compound was coadministered with a
dipeptidyl peptidase-4 inhibitor to prevent GLP-1 degrada-
tion.287 This suggests that eﬃcacy to promote GLP-1 release
may be modest. Instead, Forbes et al. suggested the primary
eﬀect of 45 was on PYY secretion, ﬁnding that gut transport
time was increased by the compound and that both food intake
and body weight were decreased in a diet-induced obesity
mouse model. Together, these results present encouraging
evidence for targeting FFA2 agonism to limit obesity, but
substantially more work will be needed to characterize the
function of this and other FFA2 agonists in vivo.
3.5.2. Orthosteric Antagonists. An alternate approach to
the identiﬁcation and use of FFA2 orthosteric agonists to deﬁne
pathophysiological roles of FFA2 is the development of
orthosteric antagonists. Such chemicals would be predicted to
block eﬀects of SCFAs in a receptor-dependent fashion. The
Figure 20. FFA2 orthosteric agonists.
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ﬁrst reported example was 46 (described by Hudson et al. as
“CATPB”) (Figure 21). On the basis of a chemical series
described in a patent from Euroscreen,288 46 both antagonized
the ability of propionate to stimulate human FFA2 in a
concentration-dependent manner and clearly acted as an
inverse agonist, as it was similarly able to inhibit constitutive
activity of the receptor.256 Although not explored in detail at
this point, these studies were also the ﬁrst to note the major
limitation on the use of 46 (and all other currently known
FFA2 antagonists): that it is speciﬁc for human FFA2 and has
no useful aﬃnity for the rodent orthologs of FFA2. Despite
this, 46 is a very useful orthosteric antagonist at human FFA2,
moving the concentration−response curves for each of the
orthosteric agonists, propionate, 39, and 40, to higher
concentrations and in a surmountable manner, suggesting it
likely binds to the orthosteric site.227 Compound 46 has also
been useful in conﬁrming that reduction in glycerol release
from SW872 human adipocytes in response to an FFA2 agonist
is indeed a reﬂection of FFA2 activation.227
Recently, a second class of highly selective FFA2 antagonists
has been described.289 A group of azetidines, of which 47
(GLPG0974) (Figure 21) is the best characterized, is also a
human-speciﬁc FFA2 antagonists. GLPG0974 is able to block
human neutrophil migration induced by acetate.289 Importantly
for potential clinical development, GLPG0974 was also shown
to block acetate-induced expression of CD11b activation-
speciﬁc epitope, a marker of neutrophil activation, in a
concentration-dependent manner in blood.289 This, therefore,
provided a biomarker to ensure target engagement of the
compound in vivo. This compound entered clinical trials in
patients displaying mild to moderate ulcerative colitis. Although
well tolerated, safe, and found to reduce neutrophil activation
and inﬂux, this was insuﬃcient to induce a measurable clinical
diﬀerence between GLPG0974 and placebo-treated patients
within 4 weeks.290
Like 46, GLPG0974 appears to be an orthosteric antagonist
of human FFA2 in that it blocks the function of a synthetic
orthosteric agonist in a surmountable and concentration-
dependent manner.257 GLPG0974 has subsequently been
radiolabeled and used to study the importance of various
amino acids of the orthosteric binding pocket to the
recognition and activity of both agonist and antagonist ligands.
This chemical displayed high aﬃnity (Kd 7.5 ± 0.4 nM) binding
to wild-type human FFA2 and lost aﬃnity to the extent that
speciﬁc binding of up to 100 nM ligand could no longer be
detected in a double R180A5.39/R255A7.35 mutant of the
receptor.257 Surprisingly, however, unlike all known FFA2
orthosteric agonists, which completely lose activity at single
mutations of these two residues, [3H]GLPG0974 maintained
high aﬃnity at the single mutants, indeed losing aﬃnity by only
2−3-fold.257 Competition binding experiments demonstrated
similar modest losses in aﬃnity for 46 at these two mutants as
well. These studies indicated that these antagonists only require
interaction with one or the other of the two arginine residues to
maintain high-aﬃnity binding to FFA2. Perhaps supporting this
is the observation that methyl esters of both 46 and of a
compound related to GLPG0974 retained high aﬃnity for
FFA2.257
A recent study has disclosed a third, chemically distinct,
series of FFA2 antagonists that lack a carboxylate, including, for
example, 48 (Figure 21).291 These compounds appear to be
relatively low-potency, inverse agonists of human FFA2,
producing such eﬀects on FFA2 with 10−30-fold lower
potency than 46.291 Limited studies suggest these compounds
are likely to also be orthosteric, despite lacking a carboxylate.
Surprisingly, several of the compounds were reported to
enhance GLP-1 secretion from NCI-H716 cells. However, it
must be noted that rather high concentrations of the ligands
were used in these studies; thus, potential oﬀ-target eﬀects
cannot be ruled out at this stage.291 Perhaps the most
interesting ﬁnding from this work is that like the other series
of FFA2 antagonists described above these compounds also
completely lack activity at rodent orthologs of FFA2. The
molecular basis for this currently remains unknown, but it will
be critical for future studies to assess this and identify FFA2
antagonists suitable for use in rodents and tissues and cells
derived from them.
3.5.3. Allosteric Agonists. The ﬁrst synthetic chemical
described as a selective activator of FFA2 was 49 (Figure
22).292 In various publications 49 has been designated
“phenylacetamide 1”,292 “4-CMTB”,293 or “AMG7703”. Iden-
tiﬁed in high-throughput screens for FFA2 agonism, 49 is a
moderately potent activator of the receptor. Moreover, in the
original publication the activity of this chemical to regulate both
Gi/o- and Gq/11-mediated end points and to activate mouse
FFA2 as well as at the human ortholog was highlighted.292
Activity at rodent orthologs allowed demonstration of the role
of FFA2 in regulating lipolysis in diﬀerentiated rat 3T3-L1
adipocytes.292 Although clearly able to function as a direct
agonist, 49 retains the capacity to activate a variety of
orthosteric binding site mutants of FFA2293 and, therefore,
acts as an allosteric agonist. Moreover, this compound acts as a
PAM of the SCFAs,292,293 increasing the observed potency of
the endogenous agonists (Figure 23). It is often noted that
allosteric ligands can display “probe dependence”, i.e., that the
detection of an allosteric eﬀect of a chemical can vary
depending on which orthosteric agonist is used.69 This, indeed,
Figure 21. FFA2 orthosteric antagonists.
Figure 22. FFA2 allosteric agonists.
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is the case for 49 as no allosteric eﬀect of this compound on the
behavior of the synthetic orthosteric agonist 39 was observed
(Figure 23).227
Subsequent studies explored the SAR of the phenylacetamide
series, but despite substantial eﬀort very little improvement in
potency over the originally reported compound has been
noted.293,294 However, Wang and colleagues did note that 49
displayed a poor pharmacokinetic proﬁle in male Sprague−
Dawley rats and, therefore, used 50 (“phenylacetamide 2”) for
in vivo studies to demonstrate an FFA2-mediated reduction in
plasma nonesteriﬁed fatty acids in wild-type mice following
intraperitoneal injection of the ligand that was lacking in
FFA2−/− animals.294 The authors did, however, report eﬀects of
this compound in FFA2−/− mice when using higher doses, and
this may limit more extensive use in vivo.294 Although also
failing to uncover compounds with signiﬁcantly better potency
than the parental 49, Smith et al. highlighted the contribution
of EL2 of the receptor and particularly of Leu173EL2 to eﬀective
allosteric communication with the SCFAs (Figure 23).293
The commercial availability of 49 has resulted in its use in a
number of functional studies. For example, Vinolo et al. used
this ligand in conjunction with SCFAs and a receptor knockout
model to record the role of FFA2 in control of chemotaxis of
mouse bone marrow-derived neutrophils.269 Equally, Nohr et
al. used a related compound 51 to examine the contribution of
FFA2 to SCFA-mediated release of GLP-1 from mouse colonic
crypts,229 while 51 was also shown to reduce ghrelin secretion
from primary gastric mucosal cells, implicating FFA2 as the
relevant receptor.259
As noted in section 3.3.3, the SCFAs appear to have diverse
eﬀects on insulin secretion depending on whether the FFA2
signaling couples to Gq/11- or Gi/o-mediated pathways. The
work of Priyadarshini et al. indicated that although SCFAs
stimulate GSIS in mouse islets, 49 had the opposite eﬀect.237 In
line with other studies on FFA2 and insulin release, this
appeared to relate to diﬀerences in the ability of the SCFAs and
49 to couple to Gi/o vs Gq/11 signaling pathways.
237 In
particular, although the authors measured robust intracellular
[Ca2+] and cAMP responses to C2, they could not measure
cAMP responses to 49, suggesting that the divergent eﬀects on
GSIS of these compounds are likely down to Gi/o vs Gq/11 bias
of these compounds. It was, however, noted that 49 retained a
level of eﬀect in islets from FFA2 knockout mice, suggesting
some oﬀ-target eﬀects. Interestingly, it had previously been
noted that 49 is only a partial agonist for activation of the ERK-
1/2 MAP kinases when compared to the SCFA C3.293 It is thus
clear that 49 should not be considered to be equivalent to
orthosteric agonists of FFA2. Indeed, a recent study aiming to
more fully characterize the function of 49 used label-free
biosensors to demonstrate that this compound displayed
unique signaling kinetics compared to orthosteric FFA2
agonists.295 Surprisingly, detailed analysis of the kinetics of 49
responses in such label-free systems suggested that this
compound activates FFA2 initially via the orthosteric binding
site, before producing a prolonged eﬀect through an allosteric
site.295 Grundmann et al. suggest this may represent a novel
pharmacological approach to regulate GPCR function;295
however, the broader importance of ligands able to sequentially
interact with diﬀerent binding sites on FFA2 and indeed the
wider GPCR family remains to be elucidated. Taken together,
although there are now important tools available with which to
study FFA2, it is obvious that further novel ligands are required
to fully explore the biology of this receptor. In particular,
identiﬁcation of each of orthosteric antagonists with broad
cross-species aﬃnity and higher aﬃnity selective orthosteric
agonists would be of major beneﬁt.
3.6. Synthetic Ligands for FFA3
Developing potent and selective ligands for FFA3 has proven
particularly challenging. While targeting allosteric binding sites
has proven successful in identifying one series of ligands
selective for FFA3 over FFA2, the potency of these compounds
remains relatively low. Moreover, unlike FFA2, where potent
orthosteric ligands have been described, to date there are no
examples of such compounds for FFA3. Despite this, some
FFA3-selective compounds based on the SCFAs themselves
have been reported.
3.6.1. Orthosteric Ligands. To date, the identiﬁcation of
synthetic orthosteric ligands for FFA3 lags considerably behind
that of FFA2. Although responding to the same group of
SCFAs, FFA3 displays a distinct SAR for the SCFAs, and as was
the case with FFA2, this led to the examination of SCAs in early
eﬀorts to identify FFA3-selective compounds.255 Although a
number of chemicals, largely those with substituted sp3-
hybridized α-carbons, were identiﬁed that showed somewhat
higher potency at FFA3, in no case was the potency and level of
selectivity suﬃcient to recommend use as an FFA3 ligand.
Despite this, at least one study has employed the SCA,
cyclopropanecarboxylic acid, as a “partially FFA3-selective”
ligand.263 Also, β-hydroxybutyrate, a metabolite produced
during ketosis, has also been described as an FFA3 ligand.
However, in diﬀerent publications it has been reported as either
an agonist247 or an endogenous antagonist244 of this receptor.
This remains to be clariﬁed, as does whether this plays a
signiﬁcant role in a physiological setting. It should be noted that
hydroxycarboxylic acid 2 (HCA2) receptor is generally
considered the key target for β-hydroxybutyrate.296
Figure 23. Pharmacology of FFA2 PAM-agonists. Functional studies
with 49 at FFA2 demonstrated that in addition to acting as an agonist
of this receptor, this ligand also enhanced the potency of C3.281,282
Simulated data demonstrating this is shown in A, where the eﬀect on
C3 potency is indicated by the dashed line. Probe dependence of the
allosteric eﬀect was found where this ligand did not allosterically
modulate the potency of the orthosteric synthetic agonist 39
(simulated data shown in B).217 The molecular basis for allosteric
communication between C3 and 49 was explored, where it was found
that replacing EL2 of FFA2 with EL2 from FFA3 resulted in a near
complete loss of allosteric eﬀect (simulated data in C).282
Chemical Reviews Review
DOI: 10.1021/acs.chemrev.6b00056
Chem. Rev. XXXX, XXX, XXX−XXX
V
3.6.2. Allosteric Ligands. Although still very limited in
scope and potency, a series of compounds has been described
that act as allosteric FFA3 ligands. These all derive from a series
of hexahydroquinolone-3-carboxamides disclosed originally in a
patent from Arena Pharmaceuticals.297 One compound from
this series, designated AR420626, was used as an FFA3-
selective agonist and found to promote GLP-1 release from
murine colonic crypt cultures.229 The same compound was also
used to show that FFA3 was not involved in the inhibition of
ghrelin secretion by SCFAs.259 However, these studies did not
extensively examine the pharmacology of the compound.
Hudson et al. demonstrated that another representative of
this series, 52 (Figure 24A), was able to directly activate human
FFA3 with modest potency while lacking activity at FFA2.298
Importantly, this study also characterized the pharmacology of
this compound in much more detail, demonstrating that it
maintained activity after mutation of the key arginine residues,
Arg1855.39 and Arg2587.35, involved in orthosteric SCFA
binding to FFA3, suggesting that the compound must be
allosteric. Moreover, in addition to showing direct agonism, the
compound also acted as a PAM, enhancing the potency of the
SCFA C3 in functional assays (Figure 24A).298
Interestingly, modiﬁcations to the hexahydroquinolone
scaﬀold of 52 had profound eﬀects on its activity at FFA3.
Such profound diﬀerences in allosteric ligand function are not
uncommon and have at times been described as “chemical
switches” to indicate that small modiﬁcations in certain parts of
a molecule will switch a compound from agonism to
antagonism or from a PAM to a NAM.299 In the case of the
FFA3 ligands, inclusion of a 2-bromophenyl group as in 53
resulted in a compound that maintained its PAM activity but
lost all intrinsic agonism; by contrast, 3- or 4-phenoxyphenyl
compounds, like 54, displayed NAM eﬀects on C3 eﬃcacy
while still maintaining their PAM eﬀect on C3 aﬃnity (Figure
24).298 As a result, 54 was described as a FFA3 PAM
antagonist, having the interesting property of becoming a
higher aﬃnity antagonist with increasing concentrations of
orthosteric agonist. Engelstoft et al. used one of these
compounds as a FFA3 antagonist to conﬁrm that FFA3 was
not involved in SCFA-mediated inhibition of ghrelin
secretion.259 Although this series of compounds represents
the best synthetic FFA3 ligands currently available, the utility of
these compounds in vivo remains highly questionable due to
their modest potency. Further, given that small chemical
modiﬁcations have profound eﬀects on activity, it would be very
diﬃcult to predict, therefore, the biological eﬀects of metabolic
products of these compounds. Considering these factors there
is a clear need to develop novel and better pharmacological tool
compounds to assess the functions of FFA3.
4. FFA4
In 2005 Hirasawa and colleagues reported that the orphan
GPCR, GPR120, was a second GPCR responsive to LCFAs.300
This receptor was activated by a wide range of LCFAs and, in
particular, by the PUFAs. The identiﬁcation of GPR120 as a
receptor for free fatty acids was, perhaps, somewhat
unexpected, however, as it is only distantly related in terms
of sequence identity to the other FFA-responsive GPCRs.
Regardless, many studies have now clearly demonstrated that
GPR120 is responsive to LCFAs, and as such, it is now oﬃcially
designated FFA4 and as a member of the FFA family of
receptors.100
Much like FFA1, the primary G protein-mediated signal
transduction pathway of FFA4 is reported to be Gq/11 (Figure
25). Activation of FFA4 has been widely reported to link to
increases in intracellular [Ca2+],130,203,300−303 and this is
blocked by the Gq/11-selective inhibitor YM-254890.
203 As
with FFA1 there are also reports that certain signals relevant to
the physiological role of FFA4 reﬂect activation of “Gi/o”-family
G proteins. For example, FFA4-mediated inhibition of ghrelin
secretion from ghrelin-containing mouse gastric cells259 as well
Figure 24. Modest structural changes to FFA3 allosteric ligands have
profound eﬀects on function. Structural variants of hexahydroquino-
lone-3-carboxamide FFA3 allosteric ligands were found to have diverse
eﬀects modulating the concentration−response to C3 at FFA3.286
While 52 was a PAM-agonist both enhancing C3 potency and acting as
an agonist on its own (simulated data in A), 53 was a pure PAM
enhancing potency of C3 with no intrinsic eﬃcacy of its own
(simulated data in B) and 54 was a PAM-antagonist, enhancing
potency of C3 while at the same time decreasing C3 eﬃcacy
(simulated data in C).
Figure 25. Signaling pathways and their associated biological
outcomes for the FFA4 receptor.
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as inhibition of somatostatin release from pancreatic islet delta
cells304 are blocked by pertussis toxin treatment, implicating
such a pathway.
In the initial studies of Hirasawa et al. a key assay used to
identify LCFAs as agonists of FFA4 was internalization of the
receptor from the surface of transfected cells.300 Indeed, FFA4
internalizes rapidly and dramatically upon agonist bind-
ing.203,303 This is correlated with robust, agonist-induced
interaction of the receptor with arrestins 2 and 3, a process
that is deﬁned largely by the phosphorylation status of a series
of serine and threonine residues within the intracellular C-
terminal tail of the receptor.203,305−309 These modiﬁcations can
involve contributions from various kinases, including both G
protein-receptor kinases (GRKs) and protein kinase C.307 The
agonist-induced interaction between FFA4 and arrestin 3 is
suﬃciently robust that this is also used routinely as a means to
assess chemical ligands for agonist activity at the recep-
tor.118,129,203,303,310,311 As scaﬀolding of arrestins and other
cellular adaptor proteins can generate noncanonical signals that
are distinct and separate from those that reﬂect G protein
activation, Prihandoko et al. explored which signals persisted
and which were ablated when various G proteins were blocked
in CHO cells transfected to express murine FFA4.309
Phosphorylation of the kinase Akt was unaﬀected by these
manipulations, while in equivalent cells expressing a mutant
form of FFA4 that is unable to be phosphorylated in response
to agonist activation, signaling to Akt was partially blocked.309
More importantly, there are also indications that arrestin 3-
mediated signaling of FFA4 plays a key role in the function of
this receptor. Speciﬁcally the eﬀects of FFA4 activation in
macrophages, acting to regulate the production of inﬂammatory
mediators, are sensitive to knockdown of arrestin 3, while
knockdown of Gq/11 did not produce this eﬀect.
312
4.1. Expression of FFA4
Initial studies exploring the expression of FFA4 in human,
mouse, and rat found the highest levels in the lower intestine,
lung, spleen, and adipose tissue.300,313,314 Detailed examination
of FFA4 expression in the intestine indicated that FFA4 is
expressed by the enteroendocrine cells on each of the L, K, and
I cells.125,300,315 At least one study has also shown more
widespread expression of FFA4 within the intestine, extending
to the intestinal epithelial cells in addition to the enter-
oendocrine cells.316 Interestingly, several factors seem to
regulate FFA4 expression in the intestine, and these may be
species and/or strain dependent. Most notably, FFA4
expression was upregulated in diet-induced obesity (DIO) rat
models,316,317 while it was downregulated in C57Bl6 mouse
DIO models.318 In studies measuring expression of FFA4
mRNA in human duodenum, a direct correlation was observed
between body mass index and FFA4 transcript levels,319
seeming to match well with the observations in DIO rats.
Interestingly, FFA4 expression levels in cultured Caco-2
intestinal epithelial cells appear to be regulated by diﬀerent
species of gut microbiota, perhaps suggesting that FFA4 may
have an indirect role in linking gut microbiota to health.320
The presence of FFA4 in adipose tissue is also now well
established, with expression increasing during adipocyte
diﬀerentiation in both mouse and human cells.312,314,321
Alterations in FFA4 adipose expression have been reported in
obese individuals; however, these studies have generated
conﬂicting results, with one suggesting upregulation322 and
the other downregulation323 of FFA4 in obesity. Obesity is
often associated with systemic inﬂammatory state, and FFA4
appears to play an important role linking inﬂammation to
obesity because FFA4 expression on human adipocytes appears
to be signiﬁcantly upregulated by exposure to macrophage
secretions.324 FFA4 is also expressed on multiple immune cell
types, but to date the most widely studied of these have been
monocytes and macrophages.312,325
Despite showing some of the highest levels of FFA4
expression, few studies have assessed the function of FFA4 in
lung. To date, a single study has suggested FFA4 is expressed
speciﬁcally in airway smooth muscle,326 and signiﬁcantly more
work will be needed to establish both the full cell-type
distribution and the biological function of FFA4 in lung. FFA4
is expressed in pancreatic islets, with limited reports ﬁnding
expression and regulation of hormone release in each of the
α,327 β,328 and δ304 cell types. Importantly, a systems genetics
approach also found that FFA4 expression in human islets is
positively correlated with insulin secretion and content and may
protect against lipotoxicity.329
Interestingly, FFA4 expression has also been demonstrated
on taste buds,330,331 where some studies have suggested it plays
a role in fat taste preference.331,332 However, several other
studies have found that although FFA4 is expressed in taste
buds and its expression levels are regulated by dietary
LCFAs,333,334 FFA4 itself is not the primary receptor for oral
fat taste preference.333,335,336 Instead, a fatty acid transporter,
CD36, was found to mediate oral fat taste preference.
FFA4 has also been reported in a number of cancers and
cancer cell lines. While studies in prostate cancer cell lines have
suggested FFA4 to have protective anticancer eﬀects,337 in
pancreatic cancer cell lines FFA4 enhanced motility, invasion,
and tumorigenicity.338 Most interestingly, FFA4 expression
appeared to be signiﬁcantly induced in human colorectal
carcinoma cells and tissues, and indeed, FFA4 appears to
function as a tumor-promoting receptor in these cells.339 Taken
together, these ﬁndings suggest FFA4 may represent a target for
novel anticancer therapeutics, but the mode of action (agonism
vs antagonism) is not yet entirely clear and may vary between
speciﬁc cancer types.
4.2. FFA4 Splice Variation
FFA4 can exist as multiple splice variants, although this is
apparently species dependent. Humans express both “long” and
“short” forms that diﬀer by a 16 amino acid insertion in the
third intracellular loop of the long form.302 Interestingly, the
long isoform was shown to be unable to elevate intracellular
[Ca2+] and, therefore, presumably is unable to interact
eﬀectively with Gq/11-family proteins (Figure 26).
303 There
are no speciﬁc data at this point that relate to the ability of this
isoform to interact with other G protein classes. Although not
fully explored at this point, the long isoform may display rather
limited tissue expression patterns compared to the short
isoform.331 Indeed, in these studies the long isoform was only
detected in colon. At odds with the studies of Watson et al.,303
Galindo et al. did observe a capacity of the long isoform to
cause Ca2+ elevation in response to various fatty acids, and in
the cases of the more high eﬃcacy ligands, 18:2 and 18:3,
diﬀerences between the splice variants were negligible.331 By
contrast, for MCFAs including 8:0 and particularly 10:0,
activation via the long isoform was substantially less eﬀective.331
It must be noted, however, that while the studies by Galindo et
al. cotransfected a very uncommonly used and non-native G
protein chimera in order to generate strong signals,331 Watson
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et al. did not.303 In contrast to humans, rodents appear to have
only a single variant that corresponds to the short isoform of
human FFA4, and this is also the case for cynomolgus
monkey.302 As such, the functional and physiological
importance of the long isoform remains uncertain.
4.3. FFA4 Genetic Polymorphisms
Like FFA1, FFA4 has received signiﬁcant interest as a potential
target for metabolic disease. In the case of FFA4 this has been
driven largely by genetic evidence linking FFA4 dysfunction in
both mouse and human to obesity and insulin resistance.322
Most notably, a single-nucleotide polymorphism in FFA4 that
produces the R254HIL3 variant in the short isoform of FFA4 (or
the R270HIL3 variant in the long isoform) has been linked to
obesity in a European population.322 Early studies suggested
that the R270HIL3 version of this polymorphism was nonfunc-
tional, and loss of function in a Gq/11-dependent Ca
2+ assay was
demonstrated.322 However, more recently an examination of
the eﬀect of this mutation on the more common short FFA4
isoform demonstrated that although the R254H variant did
display reduced function in both Gq/11- and Gi/o-FFA4
signaling, clearly some function remained.340 Further, this
study found that FFA4-arrestin interactions were not altered at
all in this variant,340 which given the link between FFA4-
arrestin signaling and inﬂamation312,325 may indicate that the
R270H/R254H variant will aﬀect the metabolic but not the
anti-inﬂammatory eﬀects of FFA4. It should also be noted that
one follow-up study using a European population found that
although this polymorphism did appear to link with fasting
glucose levels, no link was found to type II diabetes,341 while
another using speciﬁcially a Danish population found no link to
either glucose levels or type II diabetes.340 Further, this
polymorphism is rare, and its frequency varies with population.
For example, in a European population a minor allele frequency
(MAF) of 3% was reported, while in a Japanese population only
a single heterozygous carrier for the allele was identiﬁed in a
study of 1500 people, equating to a MAF less than 0.001%.
Taken together, although potentially very interesting, signiﬁ-
cantly more work is needed to understand the pharmacology
and function of this and other FFA4 polymorphisms and their
inﬂuence on metabolism and inﬂammation.
4.4. LCFAs at FFA4
Although it has become popular to describe FFA4 as the
receptor for n−3-PUFAs312,342 and the initial studies of
Hirasawa et al. did indicate that certain n−3-PUFAs, e.g., aLA
acid (18:3n−3), were among the most potent LCFAs,300 more
extensive studies provide only modest support for this idea. For
example, analysis of the widest group of fatty acids yet reported
found that nearly all MCFAs and LCFAs tested had potencies
falling within the range of 1−20 μM, and indeed, even the
SFAs, which typically have not been associated with FFA4
agonism, have comparable potency to the n−3 PUFAs at
FFA4.129 However, it must be noted that although the potency
does appear to be broadly similar across the MCFAs and
LCFAs, eﬃcacy diﬀerences among the fatty acids are apparent.
Most notably the SFAs have consistently been found to be
partial agonists at FFA4 compared to the PUFAs.129,327,331
Given these eﬃcacy diﬀerences, it is therefore likely that SFAs
and PUFAs will produce diﬀerent biological responses through
FFA4, and indeed, this is likely to have contributed to the
continued view that FFA4 is primarily a receptor for PUFAs. A
recent study has also suggested that FFA4 is activated by a
novel class of branched fatty acid, the FAHFAs.25 However, this
work has yet to be replicated, and given the low abundance of
FAHFAs in biological systems and their poor potency at FFA4,
the importance of FAHFAs as FFA4 ligands remains uncertain.
As with FFA1, the carboxylate of fatty acids appears to be
integral to recognition of the MCFAs and LCFAs by FFA4.
This was demonstrated by initial studies testing the methyl
ester of aLA, which was found to be inactive.300 Likewise,
alcohols also appear to be unable to activate FFA4, as both
oleyl alcohol and linoleyl alcohol were unable to activate FFA4,
despite their corresponding fatty acids, oleic acid (18:1n−9)
and linoleic acid (18:2n−6), each having good activity.331 FFA4
shares very little sequence identity with FFA1 and does not
possess the same key positively charged residues shown to
coordinate orthosteric ligand binding to FFA1. Instead, it
appears that the carboxylate of LCFAs interacts with FFA4
through Arg992.64. Mutation of this residue has repeatedly been
shown to result in a complete loss of LCFA function.203,303,310
4.4.1. LCFAs, FFA4, and Gut Hormone Secretion.Much
of the initial focus examining the biological function of LCFAs
through FFA4 was on a role in GLP-1 secretion from
enteroendocrine cells. In particular, the initial study deorphan-
izing FFA4 as a receptor for LCFAs also reported that LCFAs
stimulated secretion of GLP-1 from the STC-1 mouse
enteroendocrine cell line, and this eﬀect was reduced by
FFA4 knockdown.300 Several in vitro studies have reproduced
similar eﬀects in mouse and human enteroendocrine
cells,301,310,343 although in some studies FFA4 involvement
has only been implied through pharmacological interventions
and not through genetic knockdown. In contrast, studies that
have attempted to determine whether FFA4 stimulates GLP-1
secretion in vivo have generated mixed results. While some
studies have found that orally administered LCFAs stimulate
GLP-1 secretion,200,313 the only study employing genetic
knockout indicated that the eﬀect was mediated by FFA1 and
not FFA4.200 In addition to a possible role in stimulating GLP-
1 secretion from enteroendocrine cells, one study has also
suggested that FFA4 is responsible for LCFA-mediated
protection from apoptosis in these cells.344 Finally, while
GLP-1 secretion is classically associated with enteroendocrine
cells, pharmacological evidence also appears to suggest that
LCFAs can stimulate GLP-1 secretion from mouse taste buds
Figure 26. Comparison of FFA4 splice variant signaling. In human
FFA4 exists as two distinct isoforms, distinguished by the presence or
absence of 16 amino acids within IL3. While the more common short
isoform couples eﬀectively to both Gq/11 and arrestin pathways, the
long isoform couples only to arrestin pathways.291
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through activation of FFA4.345 In addition to GLP-1, FFA4 has
also been implicated in LCFA-mediated secretion of CCK from
STC-1 cells.346 However, a subsequent in vivo study concluded
that LCFA-mediated CCK secretion was most likely via FFA1
and not FFA4.124 In contrast, LCFA-stimulated GIP secretion
in vivo does appear to be through FFA4 because it was
eliminated in FFA4−/− mice.315
The hunger regulating gastric hormone, ghrelin, is also
regulated by LCFAs through FFA4. However, unlike GLP-1,
CCK, and GIP, ghrelin secretion is negatively regulated by the
LCFAs347 and inhibition of ghrelin secretion in vitro by LCFAs
has been linked to FFA4 both through pharmacological
approaches and siRNA knockdown.259,348 Although LCFAs
have been found to inhibit ghrelin secretion in vivo and this has
been suggested to be via FFA4,347 the only study utilizing
FFA4−/− mice to assess this found that, at least when delivered
orally as triglycerides in olive oil, FFA4 was not involved in
regulating in vivo ghrelin secretion.259 Interestingly, the signal
transduction pathway leading to FFA4-mediated inhibition of
ghrelin in vitro appears to be via Gi/o,
259 while the pathways
leading to the stimulation of GLP-1 and other hormone
secretion are likely through Gq/11. At present it is unclear what
factors diﬀer between cell types allowing FFA4 to couple to
Gq/11 in enteroendocrine L, K, and I cells yet to Gi/o in the
gastric ghrelin cells.
4.4.2. LCFAs, FFA4, and Adipocyte Function. FFA4 is
expressed in adipocytes and appears to increase in expression
during adipocyte diﬀerentiation. This observation led Gotoh et
al. to consider whether FFA4 may play a role in adipogenesis,
ﬁnding that adipocyte markers and lipid accumulation in 3T3-
L1 cells were signiﬁcantly reduced by siRNA knockdown of
FFA4.321 Similarly, adipogenesis has also been shown to be
inhibited in cells derived from FFA4−/− mice.322 To establish
the function of FFA4 in mature adipocytes, the primary focus
has been on how LCFAs acutely enhance glucose uptake via
FFA4 in cultured 3T3-L1 adipocytes.203,312 This eﬀect of the
LCFAs resulted from GLUT4 translocation to the adipocyte
membrane and appears to be mediated by FFA4-Gq/11
signaling.312 Longer term siRNA knockdown studies in 3T3-
L1 cells have found that FFA4 may also regulate the expression
levels of key glucose metabolism genes, including GLUT4.349
In addition to eﬀects on glucose metabolism, the n−3 fatty
acids in particular also produce anti-inﬂammatory eﬀects in
adipocytes, for example, inhibiting lipopolysaccharide (LPS)-
stimulated release of the pro-inﬂammatory adipokines:
monocyte chemoattractant protein-1 (MCP)-1 and IL-6.350
While similar eﬀects were observed with a synthetic FFA4
agonist,350 signiﬁcantly more work is needed to directly conﬁrm
the involvement of FFA4 and determine the signaling pathways
mediating these eﬀects. Finally, the n−3 PUFA eicosapentae-
noic acid (EPA) also appears to regulate expression of vascular
endothelial growth factor-A in 3T3-L1 adipocytes through
activation of both FFA4 and PPARγ,351 which may be
important to the vascularization of adipose tissue.
4.4.3. LCFAs, FFA4, and Inﬂammation. The anti-
inﬂammatory properties of the n−3 PUFAs are now very well
established,352 and a signiﬁcant amount of eﬀort has been
aimed at determining if these eﬀects are mediated by FFA4.353
The ﬁrst key ﬁnding in this area came with the observation that
LPS-stimulated secretion of the cytokines TNF-α and IL-6 in
RAW264.7 macrophages was inhibited by DHA and that this
was dependent on FFA4.312 To explore the mechanism
underlying this eﬀect, Oh et al. looked at the transforming
growth factor-β-activated kinase 1 (TAK1) signaling pathway
leading to NFκB activation. To activate this pathway TAK1
needs to interact with TAK1 binding protein (TAB1), and it
was found that FFA4 activation inhibited this by causing
arrestin 3 to sequester TAB1, thus preventing its interaction
with TAK1. A subsequent study looking further downstream of
FFA4-DHA signaling in macrophages found that inhibition of
NFκB leads to a downregulation in cyclooxygenase 2 (COX2)
expression and a reduction in the levels of prostaglandin E2
(PGE2).
354 This was also found to be arrestin 3 dependent.
Hence, the general consensus is that anti-inﬂammatory eﬀects
of FFA4 are arrestin but not G protein mediated. Contradicting
this central hypothesis, a study by Liu et al. found that anti-
inﬂammatory eﬀects of DHA were mediated by both Gq/11- and
arrestin-3-dependent FFA4 pathways.355 Confusingly, this
study found the anti-inﬂammatory FFA4-Gq/11 pathway
involved activation of cytosolic phospholipase A2 (cPLA2),
which in turn activated COX2, leading to an increase in
PGE2.
355 This is in direct contrast to an earlier study suggesting
DHA reduces COX2 expression and PGE2 levels.
354 Although
at present it is diﬃcult to fully reconcile these two ﬁndings, it
must be noted that PGE2 is known to serve both pro- and anti-
inﬂammatory roles356 and that the experimental conditions of
these two studies were markedly diﬀerent. In particular, the
study indicating DHA increased PGE2 levels measured
relatively short-term eﬀects (6 h),355 while the study
demonstrating decreased PGE2 assessed longer treatments
(24 h).354
DHA has also been shown to inhibit the inﬂammasome, a
protein complex involved in the maturation of the pro-
inﬂammatory cytokine IL-1β, in both human THP1 and mouse
bone marrow-derived macrophages.357,358 The eﬀect of DHA
was partially reduced in macrophages derived from arrestin
3−/− mice, suggesting that although arrestin 3 is involved there
are other pathways contributing to the eﬀect as well.358
Interestingly, in these studies although the n−-3 PUFA, DHA,
produced inhibition, the n−6 and n−9 LCFAs tested did
not.358 Considering that all of these LCFAs are able to activate
FFA4 with similar potency,129 it is diﬃcult to understand
immediately why DHA is able to produce an eﬀect while the
others are not. Similarly, in a study assessing TNF-α release
from mouse RAW264.7 macrophages it was found that aLA was
not as eﬀective at inhibiting LPS-stimulated TNF-α release as
DHA,203 and here both aLA and DHA are n−3 PUFAs. Taken
together, such observations that suggest apparently unique
eﬀects of speciﬁc n−3 fatty acids in producing anti-
inﬂammatory eﬀects via FFA4 do not fully match the current
understanding of the basic pharmacology of these ligands at
FFA4. It will be important for future studies to assess in more
detail whether individual, speciﬁc n−3 PUFAs activate unique
signaling pathways via FFA4, serving in eﬀect as endogenous
“biased” agonists of FFA4, or if other mechanisms account for
their unique eﬀects.
Given the established link between inﬂammation and insulin
resistance,359 it is not surprising that several studies have also
examined whether the anti-inﬂammatory eﬀects mediated by
FFA4 may link to altered insulin sensitivity. A key ﬁnding in
this area is the observation in two independent studies that
FFA4−/− mice fed a high-fat diet developed insulin
resistance.312,322 Importantly, in one of these studies the ability
of diet supplementation with n−3 PUFAs to improve insulin
resistance was absent in the FFA4−/− mice, suggesting FFA4
activation by these compounds improved systemic insulin
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sensitivity.312 However, conﬂicting studies have found no eﬀect
of FFA4 genetic knockout on insulin resistance327,360 and that
any eﬀects of the n−3 PUFAs on insulin sensitivity are not
mediated by FFA4.360 Although more work is needed to
address these discrepancies, it must be noted that the FFA4−/−
mice from these studies were from diﬀerent genetic back-
grounds, and as noted earlier in relation to FFA2 and FFA3,
this may have contributed to the diﬀerent observations.360
4.5. Synthetic Ligands for FFA4
Developing potent and selective ligands for FFA4 has proved
challenging. In particular, despite sharing very limited sequence
similarity with FFA1, it has been diﬃcult to identify ligands that
are highly selective for FFA4 over FFA1. Considering that the
majority of current biological evidence has suggested that
agonism of FFA4 would be beneﬁcial for the treatment of
metabolic and/or inﬂammatory disease,1−4,7 the majority of
work to date has focused on identifying synthetic FFA4
agonists. Indeed, several chemical classes of FFA4 synthetic
agonist have now been reported with at least some level of
selectivity for FFA4 over FFA1. By contrast, only a single,
poorly characterized compound has been described to date as
an FFA4 antagonist.
4.5.1. Orthosteric Agonists. Because LCFAs activate both
receptors, characterization of synthetic agonists at FFA1
generally also assess potential activity at FFA4 in parallel.
Thus, although GW9508 (1; Figure 9) is markedly selective for
FFA1, as noted earlier, this ligand is certainly a moderate
potency agonist of FFA4 as well.130,203 Thus, in a number of
studies on the functional roles of FFA4, GW9508 has been used
as agonist if expression of FFA1 could not be detected in the
relevant cells or tissue and/or if knockdown of FFA4 mRNA
levels provided support that GW9508 was acting as an agonist
of FFA4 in that setting.303,312,328,337,348,355,361−364
Eﬀorts to identify ligands selective for FFA4 were initiated by
modiﬁcation of known PPARγ active chemicals, with NCG21
(55) (Figure 27), being described as having modest selectivity
for FFA4 over FFA1 and a lack of activity at PPARγ.365 A
follow-up study focused on NCG21 and developed a receptor
homology model that was able to predict the correlation
between calculated binding aﬃnity of a ligand series to FFA4
and the ability of the ligands to activate ERK1/2 MAP kinases
in FFA4 expressing cells.366 A screen of a number of naturally
derived molecules highlighted grifolic acid (56) as a modest
potency, partial agonist of FFA4 but with limited activity at
FFA1.301
The ﬁrst major advance in identifying a highly potent and
selective FFA4 agonist reported in the primary literature was
the identiﬁcation and development of TUG-891 (57), derived
from an initial series of dihydrocinnamic acid-based ligands that
have activity at FFA1.118 In an assay based on recruitment of
arrestin 3 to agonist-occupied human FFA4 TUG-891 was a
potent full agonist that displayed greater than 1000-fold
selectivity over FFA1. Although somewhat less selective in
Ca2+-based assays, TUG-891 still displayed >50-fold selectivity
over FFA1 and was slightly more potent at mouse FFA4 than at
the human ortholog.118 Interestingly, despite the high potency
of TUG-891 at mouse FFA4, it also displays increased potency
at mouse FFA1,203 and, therefore, in mouse this ligand acts
essentially as a dual FFA4/FFA1 agonist, at least in end points
that reﬂect Ca2+-mediated signaling.
Although the patent literature discloses a somewhat broader
range of FFA4 active ligands,193,367 the details of function,
selectivity, and potency of many of the chemicals described
have not been reported to date in peer-reviewed studies.
However, a distinct class of diarylsulfonamide-based FFA4
ligands, identiﬁed initially in a high-throughput screen, has been
reported and described by GlaxoSmithKline.368 These lack the
carboxylate moiety long considered a hallmark of agonists at
free fatty acid receptors. Moreover, compounds such as 58
showed good selectivity against the other fatty acid receptors
and activity across key species orthologs of FFA4 but were
found unsuitable for in vivo studies because of poor
solubility.368
A further markedly selective FFA4 ligand is 59,369 which is
reported to have high potency and to be more than 1000-fold
selective for this receptor over FFA1.259 This compound
inhibited release of ghrelin with micromolar potency, an eﬀect
lacking in cells derived from FFA4 knockout mice, and
inhibited release of somatostatin from primary mouse gastric
mucosal cells.370 60 (Figure 27) has been reported as an orally
available, small-molecule FFA4 agonist also with high selectivity
for FFA4 over FFA1.325 This compound displayed high
potency at human and mouse orthologs of FFA4 in a Gq/11-
dependent assay system, while somewhat lower potency was
observed in an arrestin 3 interaction assay.325 In addition to
being relatively potent and selective for FFA4, compared to
DHA, 60 also appeared to have signiﬁcantly greater eﬃcacy
when assessed in a serum response element promoter-based
assay.325 More interestingly, in mice fed a high-fat diet, 60
improved glucose handling in oral GTT in wild-type but not
FFA4−/− mice. Treatment also decreased hyperinsulinemia,
increased insulin sensitivity, and decreased hepatic steatosis.
Moreover, as FFA4 in macrophages is known to provide anti-
inﬂammatory signals (see section 4.4.3), 60 also inhibited
macrophage chemotaxis, altered M1/M2 polarization, and
modiﬁed expression of a range of inﬂammatory markers.325
Such characteristics, if replicated in man, will provide strong
Figure 27. FFA4 ligands.
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support for the concept that agonism of FFA4 would be of
considerable beneﬁt in treatment of type II diabetes.1,193,371−373
4.5.2. Mode of Ligand Interaction with FFA4. The
molecular basis for agonist interaction with FFA4 has been
explored in some detail through both molecular modeling and
mutation studies.310 As no crystal structure of FFA4 has been
published to date, a homology model was constructed using the
crystal structure of a nanobody-stabilized active state of the β2-
adrenoceptor (PDB code 3P0G)374 as template with the
sequence of the human FFA4 short isoform. The model was
used in combination with mutagenesis data and ligand SAR
studies to probe the mode of ligand binding. The studies were
performed using aLA, the widely reported FFA1/FFA4 agonist
1, as well as the potent and selective FFA4 agonist 57 and its
analogs. Interestingly, unlike FFA1, this model suggests FFA4
ligands bind within the core 7TM structure of the receptor.
Indeed, comparing the binding pose of two of the key synthetic
FFA4 agonists, 57 and 60, suggests that despite structural
diﬀerences these compounds adopt very similar binding poses
(Figure 28A−C).
As FFA4 is distantly related to FFA1−FFA3, as noted earlier,
it does not have the positively charged arginine residues near
the top of the TM domains at position 5.39 and 7.35 present in
the other members of the FFA receptor family. However, a
positively charged Arg992.64 residue located at the top of TMII
has been implicated in several studies as a critical residue
involved in interaction between FFA4 and the carboxylate
moiety of many ligands.303,310,366 On the basis of this key
residue, several models of the putative FFA4 orthosteric
binding pocket have been constructed. The binding pocket
was indicated to be located between TMII, TMIII, and TMV−
VII. Docking of ligands into the reﬁned binding pocket resulted
in strong correlation between observed potency in a receptor-
arrestin-3 interaction assay and calculated relative binding
energies, suggesting the model to be robust, as least for the
chemical series studied.310 Alanine mutations at several residues
predicted by the model to be in close proximity to the binding
pose of 57 revealed several key residues lining the orthosteric
binding pocket. Among these W104A, F115A3.29, F211A5.42,
W277A6.48, and F304A7.36 completely abolished response to all
tested ligands in the receptor-arrestin-3 interaction assay.310 In
support of previous studies described earlier the model
eﬀectively predicted hydrogen-bond interactions between the
carboxylate moiety of the ligands and the positively charged
residue Arg992.64.310 The binding pose of 57 and other ligands
from the same chemical series highlighted hydrophobic
interactions between the phenylpropionate moiety of the
ligands and aromatic residues, including Phe1153.29,
Phe3037.35, and Phe3047.36, of the receptor. The o-biphenyl
moiety was surrounded by a narrow binding pocket lined by
residues Phe882.53, Thr1193.33, Gly1223.36, Phe2115.42,
Val2125.43, Asn2155.46, Trp2776.48, Ile2806.51, Ile2816.52, and
Thr3107.42. However, docking of GW9508 into the reﬁned
model suggested a slightly diﬀerent mode of binding within the
narrow hydrophobic binding pocket (Figure 28D and 28E).
GW9508 (1) exhibited π−π stacking interaction with
Figure 28. Similar binding poses for TUG-891 and 60 but not GW9508 in a FFA4 homology model. Binding poses of TUG-891 and 60 within the
FFA4 homology model described by Hudson et al.298 are shown both independently (A and B) and superimposed (C). The binding pose of
GW9508 is also shown independently (D) and superimposed with TUG-891 (E). Key residues lining the binding pocket that aﬀected TUG-891
potency when mutated to alanine are shown and labeled in gray, while the surface area of the pocket is shown in green.
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Phe3117.43, suggesting the importance of Phe3117.43 for the
binding of 1. However, Phe3117.43 failed to show prominent
interactions with both the PUFA aLA and other synthetic
ligands used in the study. Results from mutagenesis of
predicted key residues in the receptor-arrestin-3 interaction
assay were essentially reproduced in a Gq/11-dependent G-
protein-mediated Ca2+ mobilization assay, which suggest that
binding of ligands within the pocket predicted from the model
would probably not display bias in arrestin vs G protein-
mediated signaling. It is interesting, therefore, that Li et al.
described an FFA4 agonist series, including 61 (Figure 27),
suggested to be signiﬁcantly biased to favor signaling via
arrestin-mediated pathways.375 Although the bias of these
compounds at FFA4 has yet to be veriﬁed, it will if proven be
interesting to consider how 61 docks in the model described
above.310
4.5.3. FFA4 Antagonists. Much like FFA1, the focus on
therapeutic targeting of FFA4 has been almost entirely on
agonism. As such there has been little eﬀort to identify FFA4
antagonists. To date, only a single compound, AH 7614 (62),
has been described as an FFA4 antagonist.368 In the reported
studies this compound blocked the function of both 58 and of
LA in Ca2+ elevation assays. It also was used to conﬁrm FFA4
involvement in eﬀects of 58 on both GSIS in mouse MIN6
insulinoma cells and GLP-1 release from human intestinal NCI-
H716 cells368 and shown to block agonist-mediated phosphor-
ylation of mouse FFA4.309 However, the pharmacology of the
eﬀect was clearly consistent with a noncompetitive mode of
action, and thus, 62 most likely binds at an allosteric site on
FFA4, which is yet to be deﬁned.
5. OTHER POTENTIAL FATTY ACID-RESPONSIVE
RECEPTORS
In addition to the recognized members of the FFA family of
receptors there are at least three additional receptors that have
been reported to be activated by fatty acids. These are the
orphan receptor GPR84, reported to be activated by MCFAs,
the olfactory receptor Olfr78/OR51E2, which has been found
to respond to SCFAs, and the HCA2 receptor, reported to
respond to butyrate.
5.1. GPR84
Although GPR84 oﬃcially remains an orphan receptor, a
number of studies have highlighted the ability of MCFAs to
activate this GPCR. The signiﬁcant expression proﬁle of this
receptor in bone marrow, lung, and peripheral blood
leukocytes, particularly in neutrophils and eosinophils,376 ﬁrst
initiated potential interest in GPR84. Deorphanization studies
highlighted MCFAs with chain length between C9 and C14 as
agonists,377 with the highest potency noted for C10 and C11,
while compounds longer than C14 and shorter than C9 were
inactive. Susuki et al. also indicated that 2- and 3-hydroxylated
forms of MCFAs are also activators of GPR84.378 In general,
GPR84 is considered a pro-inﬂammatory receptor,377,378 while
in GPR84 knockout mice, responses to an inﬂammatory insult
are impaired.379 As such, there is a potential for blockade of
GPR84 to be a useful therapeutic strategy. In contrast, again
based on a GPR84 knockout mouse model, Audoy-Reḿus et al.
suggest that blockade of GPR84 might enhance cognitive
decline in diseases such as Alzheimer-type dementia,380 so
clearly much remains to be clariﬁed and the development and
use of high-aﬃnity and selective chemical tools will be vital to
do so. It is also important to note that several commonly used
inbred mouse strains carry a putative loss of function mutation
in GPR84,381 indicating selection of the appropriate mouse
strain for in vivo studies on this receptor may be absolutely
critical.
5.1.1. Synthetic Ligands for GPR84. Even in advance of
the demonstration of MCFAs as agonists at GPR84, Takeda et
al. identiﬁed both 63 and 64 (Figure 29) as low-potency
activators of this receptor (which at that time was designated
GPCR4) using a screen in which binding of [35S]GTPγS to a
receptor-Gi1 fusion protein was measured.
382 However, the
poor potency (EC50 10−100 μM) of these ligands would
appear to signiﬁcantly limit their practical use in characterizing
functional roles of GPR84. Despite this, 63 was shown to
increase secretion of the pro-inﬂammatory cytokine IL-12B
subunit from LPS-stimulated, macrophage-like RAW264.7 cells,
suggesting a pro-inﬂammatory role for GPR84.377 The
identiﬁcation of an additional, more potent, surrogate agonist
of GPR84, 65 (6-n-octylaminouracil) has further conﬁrmed a
pro-inﬂammatory function for this receptor.378 In these studies,
65 was shown to induce chemotaxis of polymorphonuclear
leukocytes as well as macrophages while also enhancing LPS-
stimulated IL-8 and TNF-α production.378 In addition to these
reported surrogate agonists, embelin (66) has also been
described in the patent literature as an agonist of GPR84.383
However, little has been described in terms of its potency at
GPR84, and its likely utility as a tool compound is limited by
known oﬀ-target eﬀects, including antagonism of X-linked
inhibitor of apoptosis protein (XIAP).384 Most recently, two
additional GPR84 agonists have been reported that are
structurally related to embelin, 67385 and 68,386 with 68 in
particular reported to have subnanomolar potency at the
receptor.
Hara et al. noted in passing that derivatives of dihydropyr-
imidinoisoquinolinones are GPR84 antagonists3 and 69 is
reported as a potent and selective antagonist of GPR84,
inhibiting GPR84 activation in a functional GTPγS binding
Figure 29. GPR84 ligands.
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assay as well as GPR84-induced neutrophil and macrophage
migration.387 Moreover, in the dextran sulfate sodium mouse
inﬂammatory bowel disease model, 69 dose-dependently
prevented disease progression.387 Galapogos progressed this
chemical into a Phase 2 proof-of-concept study in ulcerative
colitis in January 2015; however, the company recently
reported (but has not yet published) no clinical improvement
in these studies. As Nicol et al. have shown that GPR84
knockout mice do not develop mechanical or thermal
hypersensitivity subsequent to partial sciatic nerve ligation,379
it may be interesting to examine the eﬀect of GPR84
antagonists in models of nerve cell injury.
5.1.2. Mode of Ligand Interaction with GPR84. At the
current time insight into the basis of ligand binding to GPR84
is at an early stage. Nikaido et al. performed a limited
mutagenesis and modeling study using capric acid and 63 as
agonists.388 Given the very distinct chemical structures of the
two ligands, unsurprisingly, diﬀerences in the potential modes
of binding were uncovered. Perhaps surprisingly, given the
contribution of key arginine residues in the binding of fatty
acids to all the other FFA receptors, no amino acids with ﬁxed
positive charged were identiﬁed or implicated in binding of
capric acid. Two arginine residues that were mutated in these
studies, R94K3.26 and R319A6.35, did not aﬀect the potency of
this fatty acid, while a L100D3.32, but not a L100N3.32, mutation
largely eliminated function of capric acid but not of
diindolylmethane.388 Finally, a N357D7.40 mutant also all but
eliminated response to capric acid but not to 63. While the
above results indicate that these two ligands almost certainly
interact at distinct sites on GPR84,388 detailed examination of if
and how these ligands may allosterically modulate the function
of each other is currently lacking.
5.2. Olfr78/OR51E2
While historically it has only been the nonolfactory GPCRs that
have received attention in drug development, there has been a
growing appreciation that some designated olfactory receptors
are also expressed outside the olfactory system and regulate
various biological processes.26,389−392 One such olfactory
receptor expressed in kidney, mouse Olfr78 (OR51E2 in
human), is reported to be activated by micromolar concen-
trations of the SCFAs acetate and propionate to regulate blood
pressure.274,393 Expression of this receptor has also been
described in PYY-secreting enteroendocrine cells,394although
its physiological function in these cells remains unknown. More
recently, very speciﬁc expression of Olfr78 has been described
in glomus cells of the carotid body, an oxygen-sensing organ in
the carotid artery bifurcation.395 However, in this study it was
demonstrated that Olfr78 is activated by lactate in addition to
the SCFAs, and although the potency for lactate and the SCFAs
were approximately equal, this study proposed lactate as the
more likely endogenous ligand, based on its higher concen-
trations in blood.395 This remains an unanswered question, and
it may be the case that Olfr78 responds to lactate in cells that
interface directly with the blood while responding to the SCFAs
in other tissues, such as the gut, where the SCFA
concentrations are likely to be higher.
5.3. HCA2
The HCA2 receptor is a member of the hydroxycarboxylic acid
family and typically is associated with β-hydroxybutyrate (70;
Figure 30) as the endogenous agonist. However, it was earlier
indicated that fatty acids between C4 and C8 have high
micromolar to low millimolar potency at both human and
mouse orthologs of this receptor.296 HCA2 is expressed highly
in adipocytes, where it regulates lipolysis,95 as well as in various
immune cells and in the colon, where its activation appears to
result in anti-inﬂammatory eﬀects.396 Given the relatively low
potency of butyrate (C4) at HCA2 and indeed a higher potency
for its more traditional endogenous agonist, β-hydroxybutyrate,
the importance of HCA2 as a SCFA receptor remains unclear.
Perhaps it is most likely that if HCA2 is acting as a receptor for
butyrate it would do so in the colon, where the concentration
of this SCFAs is highest. Indeed, several studies have examined
the biological eﬀects of butyrate through HCA2 in the colon, for
example, demonstrating that the butyrate acts as a tumor
suppressor in the colon via activation of HCA2
397 and
implicating the receptor as a metabolite sensor of dietary
ﬁber, through its fermentation to butyrate, to regulate the
inﬂammasome.398 In addition to β-hydroxybutryate and
butyrate, nicotinic acid (71) as well as several more potent
synthetic agonists, for example, 72399 and 73,400 of HCA2 have
been described. At least one series of allosteric agonist has been
described for HCA2, exempliﬁed by 74.
401 Although no studies
have explored the basis of butyrate interaction with HCA2,
Tunaru et al. did explore the basis for nicotinic acid interaction
with this receptor.402 Of particular note, Arg1113.36 appears to
anchor the carboxylate of HCA2 agonists in much the same way
that arginine residues at positions 5.39/7.35 and 2.64 do for
FFA1−3 and FFA4, respectively. To our knowledge, there are
not currently any antagonists of the HCA2 receptor described.
Going forward, it will be important to determine whether or
not HCA2 represents a functional receptor for butyrate in vivo.
6. CONCLUSIONS AND FUTURE PERSPECTIVES
In recent times understanding of the pharmacology of the
GPCR family has expanded immensely. This has included an
appreciation that pharmacological regulation of this important
family of receptors extends far beyond simple competitive
agonism or antagonism. Such concepts have been critical in
uncovering the complex pharmacology of the FFA family of
receptors (see Table 1) and importantly is beginning to deﬁne
how these receptors may be targeted therapeutically for the
treatment of metabolic and/or inﬂammatory disease.
Although understanding of the FFA family has expanded
exponentially since their deorphanization in the early 2000s,
several critical questions remain to be answered. Most notably,
there are still many unresolved issues about how these
receptors function in a physiological setting. For example,
how do FFA1 and FFA4 produce biological responses to
uncommon LCFAs, the levels of which seem to be
Figure 30. HCA2 ligands.
Chemical Reviews Review
DOI: 10.1021/acs.chemrev.6b00056
Chem. Rev. XXXX, XXX, XXX−XXX
AD
incompatible with the concentrations required to activate the
receptors observed in vitro? Moreover, these uncommon
LCFAs are present within a complex mixture of LCFA of
which they are quantitatively minor components. For FFA2 and
FFA3, it remains challenging to clearly attribute biological
eﬀects to one receptor over the other. Moreover, it still remains
to be determined if GPR84, Olfr78, HCA2, or any other as yet
unidentiﬁed receptors also respond to FFAs in physiological
settings.
In order to progress understanding of these receptors there is
a clear need for better pharmacological tool compounds. In
particular, antagonist ligands that show function across species
and are suitable for in vivo use will be critical. For many of the
receptors there still remains a strong need for novel potent and
selective agonists as well, most notably for FFA3 where potent
and selective orthosteric agonists remain to be described and
characterized. A key goal going forward may also be to develop
novel ligands with expanded chemical diversity, given that at
present that vast majority of orthosteric ligands targeting the
FFA receptors retain the carboxylate functionality. Such
expanded chemical diversity is likely to identify ligands with
novel and perhaps bias signaling properties, which may well be
critical in deﬁning how best to target these receptors to treat
disease. Taken together, the complex pharmacology of the FFA
receptors continues to make this family an exciting possibility
for the development of novel therapeutics to treat metabolic
and inﬂammatory disease.
On a positive note, it is likely that clinical trials of further
ligands that target FFA1 will be initiated and there is growing
conﬁdence that either selective FFA4 agonists or, potentially,
molecules with combined FFA1/FFA4 activity will also be
developed. Further research is needed to provide a convincing
case for therapeutic intervention that might target FFA2 and/or
FFA3 and indeed whether agonism or antagonist might be
most eﬀective in distinct therapeutic indications. New develop-
ments in chemical ligands targeting these receptors will be
integral in providing the answers.
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Table 1. Summary of GPCRs Activated by Free Fatty Acids
fatty acids signalinga key residuesb
key tissue
expression
common biological
functions synthetic agonists synthetic antagonists
fatty acid receptor family
FFA1 MCFAs
LCFAs
Gq, Gi, Gs,
arrestin
Arg1835.39,
Asn2446.55,
Arg2587.35
pancreas islet β-
cells
enhance GSIS orthosteric and allosteric reported, mode of action not
clearly deﬁned
enteroendocrine
cells
stimulate gut
hormone secretion
FFA2 SCFAs Gq, Gi,
arrestin
Arg1805.39 ,
His2426.55,
Arg2557.35
immune cells neutrophil
chemotaxis
orthosteric and allosteric orthosteric antagonists described
only for human ortholog
enteroendocrine
cells
gut hormone
secretion
adipocytes inhibition of lipolysis
pancreatic β-cells regulation of insulin
secretion
FFA3 SCFAs Gi Arg185
5.39 ,
His2456.55,
Arg2587.35
enteroendocrine
cells
gut hormone
secretion
allosteric only allosteric NAMs reported
pancreatic β-cells inhibition of insulin
secretion
sympathetic
ganglia
FFA4 MCFAs
LCFAs
Gq, Gi,
arrestin
Arg992.64 enteroendocrine
cells
gut hormone
secretion
orthosteric only single noncompetitive antagonist
reported
adipocytes glucose uptake
immune cells,
macrophages
inhibiting cytokine
secretion
pancreas islets regulating hormone
secretion
other possible fatty acid receptors
GPR84 MCFAs Gi Leu100
3.32,
Asn3577.40
immune cells pro-inﬂammatory reported with mode of action
not clearly deﬁned
reported with unknown mode of
interaction
Olfr78 SCFAs Golf, Gs ND
c kidney regulate blood
pressure
NRd NRd
enteroendocrine
cells
HCA2 butyrate Gi, arrestin Arg111
3.36 adipocytes inhibition of lipolysis orthosteric and allosteric NRd
colon anti-inﬂammatory,
tumor suppressor
aMost commonly linked signaling pathways are in bold. bResidues reported as key to agonist function are indicated. cHas not been determined. dNo
ligands have been reported.
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